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ABSTRACT 
 
Randomized controlled trials and systematic reviews form a basis for evidence-based 
treatments of alcohol use disorders. However, generalizing the research findings of 
randomized controlled trials to clinical practice is sometimes difficult. Little is known 
about how many such treatments work in real-life treatment settings or to whom the 
results apply.  
The aim of this study was to investigate how one of the evidence-based treatments 
for alcohol dependence, cognitive behavioral therapy (CBT) combined with targeted 
(used as needed) naltrexone, works in a real-life treatment setting with a heterogeneous 
patient sample. The study specifically investigated which factors were prognostic of 
treatment dropout, treatment outcomes, and patient adherence to naltrexone. The study 
also investigated whether CBT combined with medication (naltrexone/acamprosate/ 
disulfiram) can improve patient well-being and quality of life, in addition to reducing 
alcohol consumption.  
The participants in studies I–III comprised of problem drinkers who attended an 
outpatient treatment program that combined CBT and naltrexone. The participants in 
study IV were treatment-seeking heavy drinkers who participated in a randomized 
controlled trial in which they received medication and CBT. In studies I–III, we 
evaluated the sociodemographic factors, alcohol-related factors and depressive 
symptoms of participants at treatment entry. We evaluated the change in alcohol 
consumption and symptoms of alcohol craving, as well as the patients’ adherence to 
naltrexone use during the 20 weeks of treatment. In study IV, we evaluated the change 
in the quality of life, depression, and smoking habits of participants during the treatment 
(52 weeks) and follow-up (119 weeks). 
In studies I–III, factors related to dropping out included a younger age, lower 
problem severity, lower adherence to naltrexone, and starting the treatment with 
abstinence. The alcohol-related outcomes were poorer for those with no previous 
treatment history and higher pretreatment alcohol consumption. Patients who drank 
more alcohol before and during the treatment had lower adherence to naltrexone. Poor 
naltrexone adherence was also associated with unemployment and a strong craving for 
alcohol. Study IV showed that in addition to significantly reducing drinking, combining 
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medication and CBT can improve the quality of life, depression, and smoking habits of 
those patients who commit to treatment. Participants who used disulfiram were the most 
successful in quitting smoking. 
An important finding regarding routine treatment settings was the variability in how 
problem drinkers benefited from CBT and naltrexone. Those with lower problem 
severity may benefit from shorter interventions. However, those with the most severe 
alcohol problems may require more intensive and longer treatment, as well as the use of 
medications other than naltrexone. Non-adherence to medication is a barrier to the 
effectiveness of naltrexone in a real-life treatment setting, and those with a high craving 
for alcohol may need specific interventions to enhance medication use. For those who 
commit to treatment, CBT combined with medication may improve general well-being 
and quality of life, in addition to reduced drinking. The treatment may also help patients 
quit smoking, especially those who use disulfiram during treatment.  
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TIIVISTELMÄ 
 
Alkoholiriippuvuuden näyttöön perustuvat hoitosuositukset luodaan yleensä 
satunnaistettujen ja kontrolloitujen tutkimusten sekä systemaattisten 
kirjallisuuskatsausten tuottaman tiedon perusteella. Satunnaistettujen ja kontrolloitujen 
tutkimusten yleistettävyys käytännön hoitotyöhön on kuitenkin joskus haasteellista. 
Tiedetäänkin melko vähän siitä, miten nämä hoidot toimivat luonnollisessa 
hoitoympäristössä ja kenelle ne erityisesti sopivat. 
Tämän tutkimuksen tarkoituksena oli selvittää, kuinka yksi näyttöön perustuvista 
hoitomuodoista, kognitiivinen käyttäytymisterapia (KKT) yhdistettynä kohdennettuun 
(vain tarvittaessa käytettävään) naltreksoni–lääkitykseen toimii luonnollisessa 
hoitoympäristössä ja heterogeenisessa potilasaineistossa. Tutkimuksessa pyrittiin 
erityisesti selvittämään, mitkä tekijät ennustavat potilaiden sitoutumista hoitoon, hoidon 
tuloksellisuutta ja lääkkeen käytön tunnollisuutta. Lisäksi selvitettiin sitä, voiko KKT 
yhdistettynä lääkitykseen (naltreksoni, akamprosaatti tai disulfiraami) lisätä heidän 
hyvinvointiaan ja parantaa elämänlaatua vähentyneen alkoholin kulutuksen lisäksi. 
Osallistujat tutkimuksissa I-III olivat hoitoon hakeutuvia ongelmajuojia, jotka 
osallistuivat KKT:sta ja naltreksoni-lääkityksestä rakentuvaan hoito-ohjelmaan. 
Tutkimuksessa IV tutkittavat osallistuivat satunnaistettuun ja kontrolloituun 
tutkimukseen, joka koostui lääkityksestä (naltreksoni, akamprosaatti tai disulfiraami) 
yhdistettynä terapiaan. Tutkimuksissa I-III osallistujien sosiodemografiset tekijät, 
alkoholin käyttöön liittyvät tekijät ja masennusoireet arvioitiin hoidon alussa. Muutosta 
juomismäärässä ja juomishimossa arvioitiin 20 viikon hoidon aikana. Tutkimuksessa IV 
arvioitiin muutosta osallistujien elämänlaadussa, masennusoireissa ja tupakoinnissa 
hoidon aikana (52 viikkoa) ja seurantakäynnillä (119 viikkoa).  
Tutkimuksissa I-III hoidon keskeyttämiseen olivat yhteydessä nuorempi ikä, 
vähäisempi alkoholiongelma, heikompi sitoutuminen naltreksonin käyttöön ja hoidon 
aloittaminen täysraittiudella. Hoidon tulos oli heikompi niillä, joilla ei ollut aikaisempaa 
hoitohistoriaa ja joiden alkoholinkäyttömäärä oli ennen hoitoa korkeampi. Henkilöt, 
jotka joivat eniten hoidon aikana, sitoutuivat heikoimmin naltreksonin käyttöön. 
Heikompaa sitoutumista lääkityksen käyttöön ennustivat myös työttömyys ja suurempi 
juomishimo. Tutkimus IV osoitti, että KKT yhdistettynä lääkitykseen voi parantaa 
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potilaiden elämänlaatua ja masennusoireita vähentyneen juomisen lisäksi niillä, jotka 
sitoutuvat hoitoonsa. Hoito voi myös auttaa lopettamaan tupakoinnin, erityisesti niillä, 
jotka käyttävät disulfiraamia.   
Tärkeänä havaintona käytännön hoitotyön kannalta voidaan pitää sitä, että 
luonnollisessa hoitoympäristössä potilaiden kyky hyötyä KKT & naltreksoni-hoidosta 
on vaihtelevaa. Henkilöille, joilla alkoholiongelma on lievempi, saattaa riittää lyhyempi 
hoitointerventio. Sen sijaan vaikeimmin alkoholiongelmaiset saattavat tarvita 
intensiivisempää ja pidempää hoitoa kuin tässä hoitomallissa ja hyötyä enemmän muista 
lääkityksistä. Heikko sitoutuminen lääkityksen käyttöön on yksi suurimpia esteitä 
naltreksonin tuloksellisuudelle luonnollisessa hoitoympäristössä ja henkilöt, joilla on 
korkea juomishimo, saattavat tarvita erityistä tukea lääkityksen käyttöön sitoutumiseen. 
Henkilöillä, jotka sitoutuvat hoitoonsa, KKT ja lääkitys saattaa vähentyneen juomisen 
lisäksi lisätä yleistä hyvinvointia ja parantaa elämänlaatua. Hoito voi auttaa myös 
lopettamaan tupakoinnin, erityisesti niillä, jotka käyttävät hoidon aikana disulfiraamia. 
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1 INTRODUCTION 
Alcohol use disorders are among the most important mental disorders, affecting an 
estimated 3.9% of the adult population in Finland (Pirkola et al., 2005). Globally, 4.6% 
of the burden of disease and injury has been reported to be attributable to alcohol 
(Whiteford et al., 2013). Alcohol use disorders are associated with remarkably high 
mortality, including younger age groups and those in treatment (Roerecke & Rehm, 
2013). Therefore, the existing evidence-based strategies for reducing excessive drinking 
should be widely implemented in primary care, occupational health care, and 
specialized clinics that receive patients with problem drinking. 
However, disseminating evidence-based practices, which are usually based on 
research findings from randomized controlled trials, into routine clinical settings is 
often challenging (Lamb et al., 1998; Marinelli-Casey et al., 2002; McGovern et al., 
2004). Although randomized controlled trials have long been considered as the golden 
standard in trials of alcohol dependence treatments, the generalizability of their findings 
in routine alcohol treatment settings is often poor (Rothwell, 2005). Specifically, the 
strict inclusion and exclusion criteria used in the selection of study subjects and the 
process of randomization may alter treatment settings and patient samples in a way that 
differs from usual treatments. According to Rothwell (2005), the concern among 
clinicians about the external validity of randomized controlled trials has led to the 
underuse of treatments that are effective. Studies based on routinely collected data and 
non-randomized study samples have been suggested as an important adjunct to 
randomized controlled trials (Moyer & Finney, 2002; Rothwell, 2005). However, these 
studies are still scarce. 
An important aspect in the dissemination of evidence-based treatments into routine 
clinical settings is to consider to whom the results of randomized controlled trials apply 
(Rothwell, 2005). The treatments demonstrated in randomized controlled trials cannot 
be expected to be effective in all patients and in all settings. It has been suggested that 
the results of randomized controlled trials should be reported in a way that allows 
clinicians to judge which patient groups the results can reasonably be applied to 
(Rothwell, 2005). More generally, predicting outcomes in various alcohol treatments 
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also provides an opportunity to improve treatments by identifying specific patient 
groups achieving poorer outcomes, identifying areas to target in treatment, and 
improving the accuracy of prognosis (Adamson et al., 2009). Clinical prognostic 
judgments can be aided by determining empirically established relationships using 
prospective data (Breslin et al., 1997). 
1.1. Treatment of alcohol use disorders and problem drinking 
Alcohol use disorders consist of alcohol dependence and alcohol abuse (Frances, 1994). 
The diagnostic criteria for each of these disorders are described in Table 1. Hazardous 
drinking is considered as a level of consumption or a pattern of drinking that is likely to 
result in adverse health effects (Alho et al., 2011). In Finland, hazardous drinking level 
for men has been defined as drinking more than 24 alcohol units (12 grams of pure 
alcohol) per week, 4 units per day, or more than 7 alcohol units on one occasion, and for 
women as drinking more than 16 alcohol units per week, 2 units per day, or more than 5 
alcohol units on one occasion (Alho et al., 2011). 
Although alcohol treatments typically take in patients with alcohol dependence, 
alcohol abuse, or hazardous drinking levels, individuals sometime seek treatment for 
perceived problematic alcohol use before their symptoms are severe enough to fulfill 
these diagnostic criteria. The term problem drinking is used to refer to a man whose 
alcohol consumption exceeds 14 standard drinks per week or who consumes 4 drinks 
per drinking day, or to a woman who consumes more than 7 standard drinks per week or 
3 drinks per drinking day. These alcohol consumption levels have been suggested to 
increase the risks for alcohol-related problems by the National Institute of Alcohol 
Abuse and Alcoholism (2005). 
Active screening and early detection are important in the treatment of problem 
drinking. After diagnosing the alcohol problem, a good working alliance between the 
patient and the clinician, and the use of proper psychosocial treatments form the 
cornerstone for the treatment (Alho et al., 2011). The use of pharmacotherapy with 
appropriate psychosocial treatments has been suggested to improve treatment outcomes 
(Alho & Aalto, 2013; Mann, 2004) by approximately 15–25% (Alho et al., 2011). 
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Table 1. DSM IV diagnostic criteria for alcohol dependence and alcohol abuse 
Alcohol dependence 
A maladaptive pattern of drinking, leading to clinically significant impairment or distress, as manifested 
by three or more of the following occurring at any time in the same 12-month period: 
A Marked tolerance—the need for markedly increased amounts of alcohol to achieve 
intoxication; or a markedly diminished effect with continued use of the same amount of 
alcohol 
B Characteristic withdrawal symptoms for alcohol; or drinking to relieve or avoid withdrawal 
symptoms 
C Drinking larger amounts or over a longer period than was intended 
D Persistent desire or one or more unsuccessful efforts to cut down or control drinking 
E A great deal of time spent in activities necessary to obtain, to use, or to recover from the 
effects of drinking 
F Important social, occupational, or recreational activities given up or reduced because of 
drinking 
G Continued drinking despite knowledge of having a persistent or recurring social, 
psychological, or physical problem that is caused or exacerbated by drinking 
Alcohol abuse 
A maladaptive pattern of drinking, leading to clinically significant impairment or distress, as manifested 
by at least one of the following occurring at any time in the same 12-month period: 
A Recurrent use of alcohol resulting in a failure to fulfill major role obligations at work, 
school, or home (e.g., repeated absences or poor work performance related to alcohol use; 
alcohol-related absences, suspensions, or expulsions from school; neglect of children or 
household) 
B Recurrent alcohol use in situations in which it is physically hazardous (e.g., driving an 
automobile or operating a machine when impaired by alcohol use) 
C Recurrent alcohol-related legal problems (e.g., arrests for alcohol-related disorderly conduct) 
D Continued alcohol use despite having persistent or recurrent social or interpersonal problems 
caused or exacerbated by the effects of alcohol (e.g., arguments with spouse about the 
consequences of intoxication) 
Source: Diagnostic and Statistical Manual of Mental Disorders IV (Frances, 1994) 
Note: the new DSM 5 diagnostic criteria are not included because they differ from the DSM IV criteria and 
they were not used in this study.  
 
 
1.1.1 Brief interventions 
Brief interventions are short-term counseling sessions that are aimed at addressing 
problems associated with hazardous and harmful drinking (Moyer & Finney, 2004). 
They are generally implemented by professionals who have not specialized in alcohol 
treatment, and are carried out in places such as primary health care facilities or different 
medical units (Moyer & Finney, 2004). They usually aim at reducing alcohol 
consumption to nonhazardous levels and eliminating binge drinking (Moyer & Finney, 
2004).  
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Well-designed brief intervention strategies have been found to effectively alter the 
course of harmful alcohol use (Bien et al., 1993; Maisto et al., 2001; Moyer et al., 
2002). However, there is contrary evidence concerning whom brief intervention is 
effective for. A meta-analysis by Wilk et al. (1997) revealed that heavy drinkers who 
received brief intervention were twice as likely to moderate their drinking 6–12 months 
after the intervention compared to heavy drinkers who received no intervention. In 
contrast, a study by Saitz and co-workers (2007) demonstrated that brief intervention 
was insufficient for medical inpatients. Similarly, a review by Moyer and co-workers 
(2002) found that brief interventions were only effective for persons with less severe 
alcohol problems. Brief intervention may thus best be seen as an appropriate form of 
initial treatment (Moyer & Finney, 2004), but patients who do not respond to it should 
be referred to more intensive and extensive forms of treatment, as suggested by a 
‘stepped care’ approach (Sobell & Sobell, 2000). 
1.1.2 Psychosocial interventions 
The most typical form of psychosocial treatment for problem drinking is ‘treatment as 
usual’, a supportive therapeutic relationship that combines elements from different 
therapeutic orientations (Alho et al., 2011). Specific treatments for alcohol problems 
that are based on research evidence include motivational enhancement therapy or 
motivational interviewing, coping-skills therapy, cognitive behavioral intervention or 
cognitive behavioral therapy (CBT), cue-exposure interventions, the contingency 
management approach, behavioral couple therapy, and Alcoholics Anonymous or 12-
step approaches (Emmelkamp & Vedel, 2012). Of these, there is perhaps most 
consistent evidence for the effectiveness of motivational enhancement therapy or 
motivational interviewing (Vasilaki et al., 2006), and for coping-skills therapy or CBT 
(Magill & Ray, 2009). 
Motivational interviewing has two important phases: building a patient’s motivation 
and strengthening the commitment to change (Miller & Rollnick, 1991). Motivational 
enhancement therapy is a treatment that uses the techniques of motivational 
interviewing (Miller, 1994). According to the theory presented by Miller (1983), 
motivation can been conceptualized as a state of readiness for change and, as such, it 
may fluctuate over time or from one situation to another. A lack of motivation or 
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resistance to change is seen as something that can be influenced to change in a 
particular direction (Miller, 1994). The main focus in motivational interviewing is to 
facilitate behavioral change by helping patients to resolve their ambivalent thoughts 
about the change (Miller, 1994). 
In CBT for problem drinking, the main goals are to help the patient to identify high-
risk situations for alcohol use and to develop coping strategies for these situations 
(Marlatt & Gordon, 1985). Coping skills are actions (cognitions or behaviors) that are 
encouraged to be taken in the face of challenges, such as preserving abstinence (Marlatt 
& Gordon, 1985). CBT approaches may also use self-monitoring exercises, skills 
training and cue exposure, as well as exercises to enhance motivation, increase self-
efficacy and decrease positive alcohol-related outcome expectancies (Marlatt & 
Witkiewitz, 2002).  
Cue-exposure interventions are treatments in which an addicted person is exposed to 
a variety of drug-related stimuli while self-report craving and physiological responses 
are monitored (Carter & Tiffany, 1999). Cue reactivity interventions appear to be 
effective for patients with a moderate severity of alcohol dependence (Loeber et al., 
2006). Contingency management is a procedure in which a target behavior (such as 
abstinence) is frequently monitored and positive, tangible reinforcers are provided when 
the target behavior occurs, and removed if the target behavior does not occur (Petry et 
al., 2001). Contingency management has been reported to be efficacious in treating 
alcohol-dependent patients (Petry et al., 2000). There is also evidence that behavioral 
marital therapy, a treatment that involves one’s spouse in the treatment, is effective for 
treating alcohol use disorders (Miller & Wilbourne, 2002)  
There is somewhat contrary evidence for the effectiveness of Alcoholics Anonymous 
or 12-step facilitation. Although a large clinical trial that compared the effectiveness of 
CBT, motivational enhancement therapy, and 12-step facilitation found that all three 
had similar efficacy (Project MATCH Research Group, 1998a), a more recent review by 
Ferri et al. (2006) concluded that there is insufficient scientific evidence to support the 
effectiveness of 12-step facilitation or Alcoholics Anonymous. However, it was found 
that the 12-step approaches can help patients to accept treatment and keep them retained 
in treatment more than alternative treatments (Ferri et al., 2006).  
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1.1.3 Pharmacotherapy of alcohol use disorders  
In the European Union, the pharmacological treatment of alcohol dependence includes 
four currently approved medications: disulfiram, acamprosate, and the opioid 
antagonists naltrexone and nalmefene. Disulfiram, an aldehyde dehydrogenase blocker, 
is the most traditional medication, and is used to aid abstinence. Disulfiram blocks the 
enzyme aldehyde dehydrogenase, which leads to an accumulation of acetaldehyde 
following the intake of alcohol (Heilig & Egli, 2006). The increased acetaldehyde leads 
to flushing, nausea, dizziness, tachycardia, headache, and shortness of breath (Alho & 
Aalto, 2013; Heilig & Egli, 2006). It is thought that anticipation of these symptoms 
would help patients abstain from alcohol (Alho & Aalto, 2013; Heilig & Egli, 2006). A 
review by Berglund et al. (2003) concluded that although the overall efficacy of 
disulfiram is lacking, it is seems to be effective when given under supervision. 
Similarly, a study by Laaksonen et al. (2008a) comparing the effects of three 
pharmacotherapies, disulfiram, naltrexone, and acamprosate in combination with CBT, 
in alcohol-dependent patients demonstrated that supervised disulfiram was more 
effective in reducing alcohol consumption than naltrexone or acamprosate.  
Another proven pharmacological treatment for alcohol dependence is the functional 
glutamate antagonist acamprosate, which is only available in Finland under a special 
license. Acamprosate blocks dependence-induced drinking (Rimondini et al., 2002). It 
is known to facilitate GABA-A neurotransmission and to modulate neuronal responses 
to the stimulation of both NMDA-type glutamate receptors and certain classes of 
metabotropic glutamate receptors (Fogel et al., 2013). Acamprosate has been found 
effective in supporting abstinence (Carmen et al., 2004; Mann et al., 2004).  
The main effects of the opioid antagonist naltrexone is related to reducing alcohol 
“liking” and alcohol craving (Rösner et al., 2010). It appears to work best when used as 
part of treatments that aim towards moderate alcohol use rather than abstinence (Alho & 
Aalto, 2013). Alcohol affects the opioid receptor system of the brain, which mediates 
the euphoric and pleasurable effects of alcohol, and the function of opioid antagonists is 
to block these receptors (Rösner et al., 2010). Indeed, naltrexone has been proven to 
reduce the “high” in drinking (Volpicelli et al., 1995). The use of opioid antagonists has 
been found to be an effective strategy in the treatment of alcohol dependence (Carmen 
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et al., 2004; Mann et al., 2012; Rösner et al., 2010; Srisurapanont & Jarusuraisin, 2005), 
although the effect sizes reported in many trials have been relatively small.  
It has been suggested (Sinclair, 2001) that the effect of naltrexone is highly 
dependent on the manner in which it is used. Although most randomized controlled 
trials have included daily treatment with naltrexone, an alternative approach is to only 
use it in situations where the patient anticipates a high risk of starting to drink alcohol. 
A targeted approach or as-needed use of naltrexone has been explored in a few trials. A 
study by Heinälä et al. (2001) showed that targeted medication, taken only when 
cravings occur, during a 20-week period following on from a 12-week daily naltrexone 
treatment regimen combined with coping skills therapy was effective in maintaining the 
reduction in heavy drinking. Subsequent trials by Kranzler and coworkers (Kranzler et 
al., 2003; Kranzler et al., 2009) have found that targeted administration of naltrexone in 
addition to coping skills therapy reduces drinking more than placebo.  
Another opioid antagonist, nalmefene, has also been demonstrated to reduce the total 
amount of alcohol consumed and number of heavy drinking days in patients with 
alcohol dependence when used on an as-needed (targeted) basis (Gual et al., 2013). 
Nalmefene is an opioid receptor modulator with antagonist activity at the μ and δ 
receptors, and it also has partial agonist activity at the κ receptor. The half-life of 
nalmefene is considerably longer than that of naltrexone (Bart et al., 2005). A recent 
narrative review by Niciu and Arias (2013) concludes that targeted or as-needed 
treatment with both opioid antagonists is an efficacious harm-reduction strategy for 
problem drinking and alcohol dependence. 
Future directions in the pharmacological treatment of alcohol dependence include 
aiming to form more homogeneous subgroups, such as biologically defined 
endophenotypes, who benefit from certain medications (Mann & Hermann, 2010). To 
date, it has been demonstrated that patients with a high craving for alcohol (Monterosso 
et al., 2001), those with a younger age of alcoholism onset (Tidey et al., 2008), and 
those with a positive family history of alcoholism (Monterosso et al., 2001) may have a 
better response to naltrexone. However, in a study by Capone and co-workers (2010), 
the moderating effect of a positive family history of alcoholism was not found. 
naltrexone has also been reported to most benefit individuals with the G allele of 
A118G polymorphism of OPRM1 (Chamorro et al., 2012). However, in a large 
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population study, no correlation was found between ORM1 and alcohol dependence or 
alcohol consumption (Rouvinen-Lagerström et al., 2013). 
1.1.4 Detoxification 
Among patients who consume excessive amounts of alcohol, abstinence is likely to 
cause alcohol withdrawal symptoms. These range from minor symptoms, such as 
insomnia and tremulousness, to more severe symptoms, including withdrawal seizures 
and delirium tremens (Bayard et al., 2004). Important aspects in treating withdrawal 
symptoms include reducing patients’ unspecific symptoms and subjective suffering, but 
most importantly, preventing seizures, delirium tremens, and death (Bayard et al., 
2004). Benzodiazepines are evidence-based medications for ameliorating withdrawal 
symptoms and reduce the risks associated with them (Alho et al., 2011).  
1.1.5 Combined pharmacotherapies and behavioral interventions 
The large Combined Pharmacotherapies and Behavioral Interventions (COMBINE) 
study in the US and Canada sought to address questions about the benefits of combining 
behavioral and pharmacological interventions (naltrexone and acamprosate) in alcohol-
dependent patients (Anton et al., 2006). It was found that patients who received medical 
management with naltrexone, cognitive behavioral intervention, or both fared better in 
drinking outcomes (percent of days abstinent from alcohol and time to the first heavy 
drinking day), whereas acamprosate showed no evidence for efficacy with or without 
cognitive intervention (Anton et al., 2006). It was concluded that naltrexone with 
medical management could be delivered in health care settings for patients who might 
not otherwise receive treatment (Anton et al., 2006).  
However, as presented in Table 2, in many randomized controlled trials, naltrexone 
has been shown to be especially efficacious when combined with coping skills therapy 
or CBT, where one of the therapeutic goals is to address issues related to alcohol 
craving (Marlatt & Gordon, 1985). It has been suggested that CBT and naltrexone 
reinforce their active ingredients (Anton et al., 1999), although a meta-analysis by 
Agosti and co-workers (2012) revealed that CBT did not offer benefits beyond those 
derived from the use of only study medications. Nalmefene, a newer opioid antagonist, 
has been proven to be effective when used in combination with adherence-enhancing 
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intervention (BRENDA) (Mann et al., 2012), and in a study by Karhuvaara and co-
workers (2007), even with minimal psychosocial support.  
 
Table 2. Studies comparing naltrexone in combination with different psychosocial treatments or CBT 
Clinical trial Psychosocial treatment Effect 
Kranzler et al. (2009) Coping skills therapy + 
Oslin et al. (2008) CBT 
BRENDA 
Limited therapy 
+ 
-- 
-- 
Hernandez?Avila et al. (2006) Coping skills therapy + 
Anton et al. (2005) CBT 
MET 
+ 
-- 
Balldin et al. (2003) CBT 
Supportive 
+ 
-- 
Kranzler et al. (2003) Coping skills therapy  
Monti et al. (2001) CBT  + 
Morris et al. (2001) CBT + 
Heinälä et al. (2001) Coping skills therapy 
Supportive 
+ 
-- 
Krystal et al. (2001) Supportive -- 
Chick et al. (2000) Multiple -- 
Knox & Donovan (1999) Supportive -- 
Volpicelli et al. (1997) CBT + 
Oslin et al. (1997) CBT + 
O'Malley et al. (1992) Coping skills therapy 
Supportive 
+ 
+ 
+ = Reduction in alcohol-related measures 
-- = Lower reduction in alcohol-related measures than in the comparison group or reduction non-
significant 
 
1.1.6 Treatment-specific factors vs nonspecific factors 
One controversial issue regarding selection of the best possible care for patients with 
alcohol problems is the criteria associated with treatment selection. Some trials have 
investigated the hypothesis that matching alcoholic patients to treatments based on their 
particular characteristics can improve treatment outcomes. One of these, Project 
MATCH (Project MATCH Research Group, 1998a), was a large study conducted in the 
US that investigated the effect of matching different alcohol treatments (CBT, 
motivational enhancement therapy, and 12-step facilitation) according to patient 
characteristics. The project failed to show any differences between these three 
treatments, and improvement among patients was similar across the three treatment 
forms (Project MATCH Research Group, 1998a). A similar comparative study, the 
United Kingdom Alcohol Treatment Trial (UKATT, 2005a) compared the effectiveness 
of motivational enhancement therapy as well as social behavior and network therapy 
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(Copello et al., 2002). Similarly to MATCH, patients appeared to display similar 
improvement in both treatments (UKATT, 2005a). 
While matching patients to different treatments according to their heterogeneity 
seems to add little benefit to treatment outcomes, it has been suggested that nonspecific 
factors rather than specific factors in treatments account for a considerable amount of 
the treatment outcome (Connors et al., 1997; Schneider et al., 2004; Wampold, 2001). 
Above all, these nonspecific factors appear to include a good therapeutic alliance 
between the clinician and the patient (Connors et al., 1997; Meier et al., 2005), therapist 
qualities (Najavits et al., 2000), and patients’ expectations and attributions in relation to 
treatment (Kadden & Litt, 2011; Messer & Wampold, 2002). 
1.2 Evidence-based practice in the treatment of alcohol 
problems 
Evidence-based practice is an interdisciplinary approach to clinical practice that 
originated in medicine as evidence-based medicine (Hjørland, 2011). The basic 
principles of evidence-based practice are that: a) decisions in clinical practice should be 
based on the best available evidence; b) evidence should be understood as research-
based knowledge; c) the documentation, collection, and interpretation of this evidence 
should be done in a systematic and controllable way; d) the results of this collection and 
interpretation of evidence should be published as a systematic review, which 
synthesizes knowledge from multiple primary studies; and e) explicit norms should be 
made for investigations that are most relevant (Hjørland, 2011). Norms that value 
different types of research methods are organized in a hierarchical order (Carter, 2010). 
In accordance with evidence-based practice, clinicians are encouraged to use 
empirically supported treatments with their patients. One of the most important criteria 
for empirically supported treatments is to have demonstrated the efficacy of the 
treatment over a placebo or comparison treatment in at least two independent 
randomized clinical trials (Magill & Longabaugh, 2013). However, one of the main 
problems of randomized controlled trials is that the role of nonspecific factors has often 
been ignored and it has been argued that specificity in randomized controlled trials 
cannot and should not be inferred only via the nature of the experimental contrast 
(Magill & Longabaugh, 2013). 
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1.2.1 Efficacy and effectiveness trials 
Alcohol treatment outcome studies are usually implemented as either efficacy trials or 
effectiveness trials. According to the American Psychological Association’s Task Force 
on Promotion and Dissemination of Psychological Procedures (American Psychological 
Association, 1993), treatment efficacy must be demonstrated in controlled research in 
which it is reasonable to conclude that the benefits observed are due to the effects of the 
treatment and not to chance or confounding factors, such as the passage of time, the 
effects of psychological assessment, or the presence of different types of clients in the 
various treatment conditions (see also Campbell et al., 1963). The efficacy of a 
treatment is usually demonstrated in a randomized controlled tiral, a trial in which 
participants are randomly assigned to the treatment under investigation, or to one or 
more comparison conditions. Treatments are usually performed using treatment 
manuals for which therapists have received similar and adequate training. The clinical 
utility of the treatment is usually demonstrated in effectiveness studies, in which the 
intervention is tested in a real-life practice setting (American Psychological Association, 
1993). It involves specific evaluation of the generalizability of the intervention (e.g. 
treatment settings or patient characteristics) and feasibility of the treatment (e.g. 
availability of trained therapists, patient acceptance of the intervention) (Abrahamson, 
2001).  
Efficacy and effectiveness studies emphasize different aspects of validity, i.e. the 
degree to which an investigation measures what it intends to measure. The internal 
validity of a trial refers to the degree to which the trial can attribute changes in a 
dependent variable as being caused by independent variable(s) while simultaneously 
ruling out alternative explanations (Campbell et al., 1963). In efficacy studies, internal 
validity is of particular importance. Potential threats to the internal validity of a research 
trial are presented in Table 3.   
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Table 3. Potential threats to the internal validity of a research trial 
1. Selection of the study participants: the effects may reflect pre-existing differences between 
experimental and control conditions 
2. History: the effect may be caused by some event occurring at the same time as the 
intervention 
3. Maturation: the effect may reflect a continuation of pre-existing trends or normal change 
processes 
4. Instrumentation: the effect may be caused by a change in the method of measuring the 
outcome 
5. Testing: the pretest measurement may cause a change in the posttest measure 
6. Regression to the mean: Where an intervention is implemented on units with unusually high 
scores, a natural fluctuation will cause a decrease in these scores on the posttest, which may 
mistakenly be interpreted as an effect of the intervention. The opposite (an increase) happens 
when interventions are applied to units with unusually low scores. 
7. Differential attrition: the effect is caused by differential loss of units (e.g. study participants) 
from experimental compared to control conditions 
8. Causal order: it is unclear whether the intervention preceded the outcome 
Source: Shadish et al. (2002) 
 
The external validity of a trial refers to the extent that the results of the trial can be 
generalized to other populations and settings (Campbell et al., 1963). External validity 
is of particular importance in effectiveness studies. Issues that potentially affect external 
validity are presented in Table 4.   
 
Table 4. Potential threats to the external validity of a research trial 
1. Setting of the trial: e.g. healthcare system; country; recruitment from primary, secondary or 
tertiary care; selection of participating centers; selection of participating clinicians 
2. Selection of participants: e.g. methods of pre-randomization diagnosis and investigation; 
eligibility criteria; exclusion criteria; placebo run-in period; treatment run-in period; 
enrichment strategies; ratio of randomized patients to eligible non-randomized patients in 
participating centers 
3. Characteristics of randomized participants: baseline clinical characteristics; racial group; 
uniformity of underlying pathology; stage in the natural history of their disease; severity of 
their disease; comorbidity; absolute risks of a poor outcome in the control group 
4. Differences between the trial protocol and routine practice: trial intervention; timing of 
treatment; appropriateness/relevance of control intervention; adequacy of non-trial treatment 
(both intended and actual); prohibition of certain non-trial treatments; therapeutic or 
diagnostic advances since trial was done 
5. Outcome measures and follow-up: clinical relevance of surrogate outcomes; clinical 
relevance, validity, and reproducibility of complex scales; effect of intervention on most 
relevant components of composite outcomes; who measured outcome; use of patient-
centered outcomes; frequency of follow-up; adequacy of the length of follow-up 
6. Adverse effects of treatment: completeness of reporting of relevant adverse effects; rates of 
discontinuation of treatment; selection of trial centers and/or clinicians on the basis of skill 
or experience; exclusion of patients at risk of complications; exclusion of patients who 
experienced adverse effects during a run-in period; intensity of trial safety procedures 
Source: Rothwell (2005)  
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1.2.2 External validity of randomized controlled alcohol trials 
Randomized controlled trials have been the golden standard in alcohol treatment 
research for the past few decades. However, concerns about the external validity of 
alcohol treatment trials have included the process of randomization and selection of 
study samples. Namely, participants who agree to be randomized to treatment may 
differ from those who do not (Rothwell, 2005). Another important threat to external 
validity is the use of exclusion criteria and inclusion criteria in the selection of study 
samples. For instance, it has been shown that African-Americans, low-income 
individuals, and individuals who have more severe substance abuse or psychiatric 
problems are disproportionately excluded from alcohol treatment trials in comparison to 
real-world samples seen in clinical practice (Humphreys & Weisner, 2000). The 
exclusion of individuals with psychiatric disorders or other substance use problems may 
be particularly problematic from the point of view of external validity, because alcohol 
use disorders are highly correlated with both of these in the general population (Hasin et 
al., 2007). 
In many trials that have examined the efficacy of CBT and naltrexone, it has been 
customary to exclude patients with major psychiatric or medical comorbidities (Anton 
et al., 2005; Heinälä et al., 2001; Hernandez?Avila et al., 2006; Kranzler et al., 2009). In 
addition, in many studies, only patients who fulfill the criteria for alcohol dependence 
(Heinälä et al., 2001; Killeen et al., 2004; Krystal et al., 2001; Mann, 2013) or those 
with high-risk alcohol consumption levels (Heinälä et al., 2001; Hernandez?Avila et al., 
2006; Kranzler et al., 2009) have been included in the study sample. 
Despite their limitations, randomized controlled trials are still the most reliable way 
to determine whether a cause–effect relation exists between a treatment and outcome 
and for assessing the cost-effectiveness of a treatment (Sibbald & Roland, 1998). 
However, more research is needed to test how evidence-based alcohol treatments work 
in real-life treatment settings using heterogeneous patient samples, including patients 
who have different comorbidities. As Moyer and Finney (2002) suggest, instead of 
debating the superiority of one versus the other, randomized and non-randomized 
research trials should be considered as complementary forms of treatment evaluation in 
alcohol treatment trials.  
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1.3 Predictors of treatment outcome  
The prediction of treatment outcomes is a challenging task for a clinician who works 
with alcohol-dependent patients. The clinical prediction of human behavior may be 
inferior to formal and statistical methods (Grove et al., 2000), which has been explained 
by Grove and co-workers (2000) as due to “clinicians tendency to ignore base rates, 
assign non-optimal weights to cues, failure to take into account regression toward the 
mean, and failure to properly assess covariation.” They also point out that clinicians 
often do not receive sufficient feedback on the accuracy of their judgments, which they 
could use to modify their possible judgment bias. Therefore, it is important to examine 
which patient- and treatment-related variables can be used to make a more accurate 
prognostication of treatment (Kraemer et al., 2001). 
Another issue related to the importance of effective treatment planning is the cost-
effectiveness of treating alcohol problems. Although there is evidence for effectiveness 
of brief interventions (Bien et al., 1993; Maisto et al., 2001; Moyer et al., 2002), it is 
clear that a portion of problem drinkers do not change their alcohol use in response 
them (Moyer et al., 2002; Saitz et al., 2007) and may need more intensive and longer 
treatments. Improved prognostication allows a clinician to improve treatment planning 
with respect to the intervention type, duration, and intensity (Kadden & Skerker, 1999). 
Different predictors of alcohol treatment outcomes can be related to: a) patient-
related factors, such as socio-demographic and internal factors (e.g. motivation for 
treatment, motivation for change, and alcohol-related self-efficacy); b) clinical factors, 
such as the comorbidity of other symptoms or disorders and the severity of the alcohol 
problem; and c) the treatment setting, such as the modality of the treatment (outpatient 
vs. inpatient treatment), length and intensity of the treatment, therapist qualities, and 
therapeutic alliance. Factors related to treatment outcomes can also be divided into 
predictors, mediators, and moderators. A predictor variable of a treatment’s 
effectiveness is here referred to as a variable that is known to predict the value of the 
treatment outcome. A mediator of a treatment’s effectiveness is a variable that 
intervenes temporally between the initiation of treatment and the alcohol-related 
outcome variable (Longabaugh, 2007). A moderator is a variable that identifies 
subgroups of patients within the population who have different effect sizes (Kraemer et 
al., 2002).  
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1.3.1 Treatment dropout and predictive factors 
One of the most pervasive phenomena in treating alcohol problems is the frequency 
with which patients drop out of treatment. In a comprehensive review by Baekeland and 
Lundwall (1975), it was reported that 52–75% of alcoholism outpatients drop out before 
the fourth session. In more recent studies, reported dropout rates from alcohol treatment 
services have been within the range of 23–60% (Mammo & Weinbaum, 1993; McCaul 
et al., 2001; Wickizer et al., 1994). In a large, retrospective analysis of the discharge 
statuses of 48 299 patients entering alcohol treatment services in Scotland, it was found 
that more than half of entries to alcohol misuse services resulted in an unplanned 
discharge (Newham et al., 2010). 
Dropping out of treatment is often seen as a sign of noncompliance, resistance, or 
a failure of treatment, and there is indeed evidence that time spent in treatment 
correlates with a positive post-treatment outcome (Gottheil et al., 1992; Moos & Moos, 
2003a; Welte et al., 1981). However, it is important to note that dropping out may not 
always occur for negative reasons. Patients may report significant levels of satisfaction 
and problem improvement despite attending fewer appointments than originally 
intended (Pulford et al., 2006; Scamardo et al., 2004). Pulford and co-workers (2006) 
have argued that instead of interpreting dropout as a failure of treatment, it can be 
understood as a failure of treatment fit, meaning that a patient leaves in response to the 
treatment not being optimally suited to his or her presenting problem.  
Sociodemographic predictors of dropout from treatments for substance misuse have 
included a younger age (Brorson et al., 2013; Elbreder et al., 2011; Mammo & 
Weinbaum, 1993; McKellar et al., 2006; Wickizer et al., 1994) and lower educational 
level (King & Canada, 2004; Mammo & Weinbaum, 1993; Wickizer et al., 1994). The 
results have been mixed in terms of gender, with some studies showing poorer treatment 
participation among women (King & Canada, 2004; Mammo & Weinbaum, 1993; 
McCaul et al., 2001; Wickizer et al., 1994) and others finding no differences between 
genders (Elbreder et al., 2011; Veach et al., 2000; Wickizer et al., 1994). Other patient-
related predictors of dropout include cognitive deficits (Brorson et al., 2013), 
personality disorders (Brorson et al., 2013), and lower levels of psychological distress 
tolerance (Daughters et al., 2005). Better treatment retention has been reported among 
those with higher depressive syndromes at treatment entry (MacMurray et al., 1987). 
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Studies that have investigated substance-related factors related to dropout have 
demonstrated that dropping out is more common for those with a lower severity of 
alcohol dependence (Elbreder et al., 2011; McKellar et al., 2006), a shorter history of 
substance misuse (Wickizer et al., 1994), and a high craving for alcohol at the time of 
treatment entry (Soyka et al., 2003). Treatment-related factors predictive of treatment 
retention have included the use of disulfiram during treatment (Elbreder et al., 2010) 
and receiving a rapid initial response and individual attention in treatment (Stark, 1992), 
which have both been reported to relate to better treatment retention. A weak 
therapeutic alliance has been reported to increase the risk of dropout (Brorson et al., 
2013), whereas a strong therapeutic alliance seems to be related to better treatment 
retention (Meier et al., 2005) 
1.3.2 Patient characteristics and clinical factors as predictors of outcomes 
A systematic review by Adamson and co-workers (2009) examined 63 published papers 
describing the findings from 51 unique treatment outcome studies collating 31 baseline 
predictors of alcohol use disorder treatment outcomes. The most consistent predictors 
overall were dependence severity, psychopathology ratings, alcohol-related self-
efficacy, motivation, and the treatment goal. The two predictor variables that accounted 
for the greatest variance when controlling for broader methodological variables were 
baseline alcohol consumption and dependence severity. Predictably, negative outcomes 
were related to more severe alcohol dependence, higher psychopathology ratings, and 
higher alcohol consumption. In contrast, high alcohol-related self-efficacy, high 
motivation, and having a treatment goal of abstinence were related to better outcomes.  
In another review by McKay and Weiss (2001), which examined 12 studies, the most 
consistent baseline predictors of the outcome were the pretreatment level of substance 
use and psychiatric severity. Lower problem severity predicted better outcomes, but the 
nature of the relationship and psychiatric severity varied. Motivation and coping skills 
were also related to the outcome. Gibbs and Flanagan (1977) identified lower 
psychopathology, higher Wechsler arithmetic scores, a steady work history, being 
married/cohabiting, employment, a higher status occupation, a history of fewer arrests, a 
history of Alcoholics Anonymous contact, and a higher social class as “somewhat 
stable” predictors of a better outcome. 
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In contrast to stable variables, some predictor variables may be considered more 
malleable and may therefore be identified as important targets for manipulation during 
the treatment process (Adamson et al., 2009). For example, patients’ alcohol-related 
self-efficacy, employment status, or amount of social support may be factors that 
change during the course of treatment and lead to positive treatment outcomes. The 
amount of drinking during treatment is obviously likely to be related to the post-
treatment outcome. Indeed, it has been demonstrated that higher alcohol consumption 
during treatment is related to higher alcohol consumption in the post-treatment period 
(Breslin et al., 1997). 
1.3.3 Treatment characteristics as predictors of treatment outcomes 
Treatment characteristics that predict or mediate treatment outcomes may be related to 
active ingredients of the treatment, the nonspecific factors in the treatment, or modality 
of the treatment. While the support for the influence of active ingredients of different 
treatments on treatment outcomes has been weak (Longabaugh et al., 2005; Magill & 
Longabaugh, 2013; Meier et al., 2005; Project MATCH Research Group, 1998a), there 
is consistent support for the effect of the therapeutic alliance on treatment outcomes 
(Najavits & Weiss, 1994; Project MATCH Research Group, 1998b). Therapeutic 
alliance can be defined as the collaborative relationship between the clinician and the 
patient, including an affective bond between the patient, and the therapist and the 
patient’s and therapist’s ability to agree on treatment goals and tasks (Martin et al., 
2000). 
According to a review by Najavits and Weiss (1994), the primary therapist 
characteristic associated with higher effectiveness of treatment outcomes is the 
possession of strong interpersonal skills. These skills include empathy, supportiveness, 
warmth, and understanding (Lafferty et al., 1989; Najavits & Weiss, 1994). However, 
according to a review by Meier and co-workers (2005), the therapeutic alliance appears 
to influence early improvements during treatment, but is an inconsistent predictor of 
post-treatment outcomes in different substance use treatments. Meier and co-workers 
(2005) concluded that too little is known about what determines the quality of the 
relationship between substance abusers and clinicians. Patients’ perceptions of different 
characteristics of the treatment and their active participation in the therapeutic process 
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are also likely to influence the treatment outcomes. Indeed, it has been demonstrated 
that patients’ involvement in therapy and perception of treatment efficacy are related to 
positive outcomes (Long et al., 2000). 
One potential contributor to treatment outcomes is related to the modality of the 
treatment. Although there is no consistent support for the use of inpatient care over 
outpatient care (Mattick & Jarvis, 1994), it has been suggested that certain types of 
patients may benefit more from placement in one treatment setting over another (Finney 
et al., 1996; Rychtarik et al., 2000). Rychatarik and co-workers (2000) suggested that 
particularly patients who are low in cognitive functioning and those with more severe 
alcohol problems may benefit more from inpatient care. There is also some evidence 
that the length of stay may be related to treatment outcomes (Gottheil et al., 1992; Moos 
& Moos, 2003b). 
1.3.4 External factors as predictors of treatment outcomes 
External factors, such as life events outside the treatment, may have a strong influence 
on treatment outcomes (Longabaugh, 2007). Another factor that may have an influence 
is social support. Beattie and Longabaugh (1999) found that alcohol-specific and 
general social support were important in maintaining abstinence in the short term (3 
months) after the treatment, but alcohol-specific support was most important 15 months 
post-treatment. Similarly, Billings and Moos (1983) who compared recovering and 
relapsed alcoholics after treatment, found that recovering alcoholics made effective use 
of coping strategies and social support, and successfully avoided environmental 
stressors compared to those who relapsed. There is also evidence that participation in 
Alcoholics Anonymous during or after outpatient treatment may be related to better 
treatment outcomes (Morgenstern et al., 1997; Ouimette et al., 1998).  
1.3.5 Medication adherence  
Despite the relatively strong evidence supporting the use of pharmacotherapy as part of 
alcohol treatment, medication adherence is particularly low in the alcohol-dependent 
population (Pettinati, 2006a). This is problematic, because the effect of naltrexone, for 
instance, has been demonstrated to be associated with medication adherence (Baros et 
al., 2007; Chick et al., 2000). Indeed, the modest effect sizes for naltrexone reported in 
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systematic reviews and meta-analyses may at least partly be attributable to variability in 
naltrexone adherence rates (Swift et al., 2011).  
In trials with daily use of naltrexone, the reported medication adherence rates have 
ranged from 40% to 88% (Carmen et al., 2004; Namkoong et al., 1999). The non-
adherence rate for disulfiram is known to be as low as 80% (Fuller et al., 1986). 
Similarly, a meta-analysis by Carmen and co-workers (2004) reported an average 
adherence rate of only 53% to acamprosate in treatments lasting from 3 to 24 months. In 
studies exploring the targeted use of naltrexone, the reported adherence rates have 
generally been more consistent, around 86–87% (Hernandez?Avila et al., 2006; 
Kranzler et al., 2003; Kranzler et al., 2009). However, in real-life treatment settings, 
medication adherence is likely to be much lower than in clinical trials, in which 
medication use is usually monitored intensively and where the participants usually 
receive their study medication at no cost. Indeed, studies based on retrospective 
analyses of prescription claims databases by Kranzler and co-workers (2008) and 
Hermos and co-workers (2004) have reported that only 14–22% of patients who had an 
initial prescription for naltrexone persisted in picking up the medication after 6 months.  
Certain factors that may affect adherence with naltrexone have been reported in the 
literature. Although naltrexone in generally well tolerated, it may cause unpleasant side 
effects for some patients, such as nausea and vomiting (Streeton & Whelan, 2001). 
Unpleasant side effects are suggested as one reason for non-compliance (Rohsenow et 
al., 2000; Volpicelli et al., 1997). Other predictors of poor adherence have been 
suggested to include a lack of belief in the utility of naltrexone in managing alcohol use 
(Rohsenow 2000), younger age (Baros et al., 2007; Gueorguieva et al., 2013), greater 
drinking severity (Gueorguieva et al., 2013), dissatisfaction with medicine 
(Gueorguieva et al., 2013), and a lack of benefit (Gueorguieva et al., 2013).  
Alcohol-dependent patients who use any alcoholism medications have been reported 
to have fewer detoxification admissions, alcoholism-related inpatient care and 
alcoholism-related emergency department visits in the 6 months following medication 
initiation in comparison to patients who have not received alcoholism medication (Mark 
et al., 2010). Therefore, in addition to promoting the use of pharmacotherapy as an 
adjunct to psychosocial treatment in substance abuse clinics and general practices, it is 
important to understand the factors that may lead to low adherence. Identifying and 
32 
 
tackling the factors associated with poor adherence may lead to improved treatment 
planning and enhanced effectiveness. 
1.4 The effect of alcohol treatments on depression, quality of 
life and smoking 
Depressive symptoms and depressive disorders are common among patients with 
alcohol-related disorders (Driessen et al., 2001; Hasin et al., 2007; O’Donnell et al., 
2006), and the co-occurrence of depression may be an important determinant of 
treatment seeking (Lynskey, 1998). Comorbid depressive symptoms are also associated 
with an increased risk of relapse after treatment (Burns et al., 2005; Curran et al., 2000; 
Driessen et al., 2001). Therefore, it is important to treat depression along with alcohol 
use. While antidepressants used with psychosocial treatments alleviate depressive 
symptoms, they appear to have relatively little impact on reducing alcohol drinking 
(Pettinati, 2004). However, there is evidence that combined pharmacotherapy that 
addresses both depression and alcohol use may lead to improved outcomes in both of 
these (Pettinati et al., 2010). 
Alcohol dependence also appears to be associated with a markedly decreased quality 
of life (QL) (Foster et al., 1999). However, achieving and maintaining a marked 
reduction in drinking, even without complete abstinence, has been found to be 
associated with significant increases in QL (Donovan et al., 2005; Foster et al., 1999; 
Frischknecht et al., 2013). As LoCastro and co-workers (2009) suggest, when 
evaluating alcohol treatment effectiveness, it is important to include secondary 
nondrinking outcomes, such as QL, in clinical alcohol-treatment trials.  
In addition to an increased risk of depression, as many as 80% of alcohol-dependent 
individuals smoke cigarettes (Miller & Gold, 1998). Alcohol-dependent smokers also 
experience more depression, sleep disturbances and symptoms of craving for nicotine 
(Hertling et al., 2005). Accordingly, it may be important to take into account the issue 
of smoking when planning treatment and assessing treatment outcomes. 
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2 AIMS OF THE STUDY 
Despite the large number of randomized controlled studies on cognitive behavioral 
therapy and naltrexone, studies that have investigated CBT and targeted naltrexone in a 
real-life treatment setting appear to be lacking. Little is also known about which patient-
related factors are associated with treatment outcomes.  
The aim of this study was to investigate how the combination of CBT and targeted 
(used as needed) use of naltrexone works in a community outpatient treatment setting 
consisting of a heterogeneous sample of patients. The study also investigated whether 
the combination of medication (acamprosate, disulfiram or naltrexone) can improve 
patients’ general well-being, quality of life and smoking habits, in addition to reducing 
alcohol use. The specific aims of the study were as follows: 
 
1. To determine the pretreatment and treatment-related factors that are related to 
treatment dropout;  
 
2. To determine the pretreatment and treatment-related factors that are related to 
treatment outcomes evaluated as the change in alcohol consumption and symptoms of 
alcohol craving in patients during treatment; 
 
3. To determine the pretreatment predictors of patient adherence to the targeted use of 
naltrexone in situations of drinking alcohol;  
 
4. To investigate using a randomized study protocol  how the combination of 
medication (acamprosate, disulfiram or naltrexone) and CBT can affect patients’ 
symptoms of depression, quality of life, sleeping, and smoking habits, in addition to 
reducing alcohol consumption. 
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3 METHODS 
3.1 Selection of the participants 
3.1.1 Participants in studies I–III 
The participants in studies I-III were 476 problem drinkers aged 20–70 years who 
contacted a private Finnish outpatient clinic providing CBT combined with naltrexone 
for the treatment of problem drinking between November 1998 and November 2001. 
The following exclusion criteria were used: the use of opiates or opiate-based 
painkillers, severe untreated somatic problems, serious dysfunction of the liver (ASAT 
and ALAT >200), risk of suicide, breastfeeding women, or women who were pregnant 
or planning pregnancy. Those (n = 98) who decided not to enroll in the treatment 
program after the initial interview were excluded from the study. Due to missing data in 
all variables other than age and gender, six patients were excluded from the samples. No 
other exclusion criteria were applied.  
The final study sample in study I consisted of 372 participants. The baseline 
characteristics of the sample are described in Table 5. The study samples were smaller 
in studies II–III because, due to practical reasons, no drinking diaries were collected at 
the clinic after June 2002. In study II, after applying the above selection criteria, the 
final study sample consisted of 315 participants. In study III, the final study sample 
consisted of 299 participants, because 16 participants were excluded for not committing 
to the reporting of their naltrexone use during the treatment. Due to minimal exclusion 
criteria, the patient samples included those with comorbid psychiatric and/or medical 
disorders (54.4% in study I, 51.8% in study II, and 52.4% in study III). All participants 
signed a written informed consent form. Ethical permission for the study was granted by 
the Ethics Committee of the Hospital District of Helsinki and the Province of Uusimaa. 
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Table 5. Baseline patient characteristics in study I (n = 372)  
          n % M (SD) 
Age 366  46.0 (8.6) 
Gender 372   
Female  34.9%  
Marital status 356   
Not cohabiting  29%  
Education 295   
High/higher intermediate  40.0%  
Lower intermediate  24.8%  
Basic or none  35.2%  
Employment 363   
Employed  70.0%  
Unemployed  18.7%  
Retired or other  11.3%  
Alcohol consumption pattern   342   
                     Regular drinking    85.1%  
                     Episodic heavy drinking    14.9%  
Alcohol consumption pattern (regular drinkers) 285   
Low-risk drinking  15.1%  
High-risk drinking  84.9%  
Problematic drinking in years 352  10.5 (7.7) 
DSM IV Alcohol dependence symptoms 296  6.6 (2.0) 
DSM IV Alcohol dependence diagnosis 296   
No  4.0%  
OCDS  328  17.5 (5.8) 
BDI  300  8.0 (5.8) 
A first-degree relative with alcoholism   372   
                     No   44.9%  
Psychiatric/medical disorders 307   
No  45.6%  
Previous treatment history    313   
 No     53.4%  
M = mean; SD = standard deviation 
Low risk: ≤24 standard drinks for men and ≤18 standard drinks for women 
High risk: ≥24 standard drinks for men and ≥18 standard drinks for women 
DSM IV = Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (Frances, 1994) 
OCDS = Obsessive Compulsive Drinking Scale (Anton et al., 1995; Anton et al., 1996) 
BDI = short version of the Beck Depression Inventory (Beck & Beck, 1972) 
Note: due to missing data, n varies between 285 and 372. 
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3.1.2 Participants in study IV 
The participants in study IV were 243 men and women aged 25–65 years who were 
voluntarily seeking outpatient treatment for alcohol problems at three outpatient 
treatment centers for alcohol problems (A clinics) and three occupational health-care 
units in cities in southern Finland between 2000 and 2005. For inclusion, the patients 
had to meet the ICD-10 criteria for alcohol dependence (WHO, 2010). Detoxification 
was not required and at least one month had to have elapsed since the last date of the 
previous treatment. The exclusion criteria in the study were: clinically significant 
symptoms of alcohol withdrawal; significant recently diagnosed psychiatric disease 
(psychosis or suicidal tendency that appeared during the initial interview); a current 
psychiatric disease demanding special treatment or medication, including drug 
dependence other than alcohol or nicotine dependence determined by the DSM-IV 
(Frances, 1994); current use of any opioids with the 4 weeks before screening; a 
significant brain, thyroid or kidney disease; an uncompensated heart disease; a clinically 
significant liver disease (cirrhosis, alcohol hepatitis, or alanine transaminase (ALAT) 
<200); or pregnancy, nursing, or women who refused to use a reliable birth control 
method.  
The study protocol, written information for subjects, and consent form were 
approved by the Ethical Committee of Helsinki and Uusimaa Hospital District, the 
Turku Health Care Organization Ethical Committee, and the Finnish National Medical 
agency. The study was conducted according to the principles of the International 
Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, guidelines for Good Clinical Practice, and the 1964 
Helsinki Declaration. All subjects had to be able to read and understand the patient 
information sheet and sign the informed consent. All participants were free to finish the 
study medication whenever they wanted, and were not paid or reimbursed for their 
participation.  
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3.2 Measures 
3.2.1 Pretreatment alcohol use 
In the protocol of studies I–III, the data on the participants’ characteristics and 
backgrounds were obtained from the initial structured screening interview with a 
physician at the clinic. A structured clinical interview, MINI (Sheehan et al., 1997), was 
used at the treatment entry interview to assess the total number of DSM-IV (Frances, 
1994) alcohol dependence symptoms for each patient and for categorizing whether they 
had alcohol dependence or not. The participants were also asked to evaluate the age at 
which their alcohol drinking became problematic. Based on this information, the length 
of their problematic drinking was calculated in years. The participants were interviewed 
in order to obtain their medical and psychiatric history, including the use of any 
medications and concerning their family history of alcoholism.  
A daily drinking and naltrexone use diary was introduced to the participants of 
studies I–III at treatment entry, and they were taught how to calculate their alcohol 
consumption in standard units (12 g of pure alcohol) for the preceding month. An 
average amount of weekly consumption of alcohol (measured as the number of standard 
12 g drinks) was calculated for regular drinkers. Accordingly, the patients were 
categorized into regular drinkers (consuming alcohol weekly) and episodic heavy 
drinkers (those whose primary problem was occasional, not weekly heavy drinking). 
Regular drinkers were further categorized into those with higher-risk alcohol 
consumption level (weekly alcohol consumption of ≥ 24 standard drinks for men and ≥ 
18 standard drinks for women) and lower-risk alcohol consumption level (weekly 
consumption of <24 standard drinks for men and <18 standard drinks for women). This 
categorization was the same as used in studies by Kranzler and coworkers (Kranzler et 
al., 2003; Kranzler et al., 2009) examining the efficacy of targeted naltrexone and CBT 
for treating problem drinking. Episodic heavy drinkers (n = 51) were not categorized 
according to their weekly consumption group, since they were typically unable to 
describe the amounts of alcohol consumed during their heavy drinking episodes, which 
often lasted for a period of several days. In study I, patients were also categorized into 
those who started the treatment with abstinence (for the first 2 weeks) and those who 
started the treatment with drinking.  
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In study IV, the severity of the alcohol problem was measured with the Alcohol Use 
Disorder Identification Test, AUDIT, and the Severity of Alcohol Dependence Data, 
SADD (Babor et al., 2001; Davidson & Raistrick, 1986; Saunders et al., 1993) during 
the study period (52 weeks) and follow-up periods (up to 1.5 years). Smoking habits 
were examined with simple ‘yes or no’ questions at weeks 0, 12, 26, and 52. 
3.2.2 Alcohol craving 
In studies I–III, a Finnish translation of the Obsessive Compulsive Drinking Scale, 
OCDS (Anton et al., 1995; Anton et al., 1996), was used to measure the craving for 
alcohol at treatment entry. The OCDS has been suggested as a useful instrument in 
evaluating therapeutic approaches such as CBT (Anton et al., 1996). In addition to 
calculating the total score for the OCDS, the three factors ascertained by Roberts et al. 
(1999) were calculated for the purpose of studies I and III. The subscales are interpreted 
as “resistance/control impairment,” “obsession,” and “interference,” and they have been 
found to distinguish between subjects who remained abstinent, exhibited "slip" 
drinking, or relapsed to heavy drinking during the 12 weeks of active treatment (Roberts 
et al., 1999). In addition to the OCDS, a 10 cm Visual Analogue Scale (VAS) was used 
to measure the intensity of the craving during each therapy session. In the VAS, patients 
were asked to imagine themselves in a situation where they typically drank alcohol and 
evaluate how strong their desire to consume alcohol was at that moment, on a scale 
ranging from “no desire” to “if alcohol were available, I could not resist the urge to 
drink.” Although scales such as the Visual Analogue Scale have been criticized for 
relying exclusively on the patient’s interpretation of craving, significant correlations 
have been found between the VAS and the OCDS (Anton et al., 1996). 
3.2.3 Alcohol use, smoking, and medication use during treatment 
The participants of studies I–III were instructed to keep a daily record of their intake of 
alcohol (reported in standard units) and report their as-needed use of naltrexone in 
drinking diaries during the course of the treatment. Compliance measurements based on 
daily diaries have been shown to provide information similar to data obtained using 
electronic medication-use monitoring (Feinn et al., 2003). During each therapy session, 
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drinking diaries were thoroughly monitored and their information was copied and filed 
at the clinic. If the patient forgot his/her drinking diary, it was filled in retrospectively.   
In study IV, changes in alcohol-related symptoms were monitored with AUDIT 
(Babor et al., 2001; Saunders et al., 1993) and SADD (Davidson & Raistrick, 1986) 
during the study period (52 weeks) and follow-up periods (up to 1.5 years). Alcohol 
consumption and the use of study medication during the 52 study weeks were also 
assessed using a retrospective drinking diary (Poikolainen & Kärkkäinen, 1983). 
Smoking habits were examined at weeks 0, 12, 26, and 52 by asking the patients 
whether they smoked or not. 
3.2.4 Quality of life and depressive symptoms 
For studies II–III, patients’ depressive symptoms were evaluated at baseline with a short 
version of the Beck Depression Inventory (Beck & Beck, 1972). In study IV, depression 
was evaluated with the regular version of the Beck Depression Inventory (BDI) (Beck et 
al., 1961) and the Depression Scale (DEPS) (Salokangas et al., 1995) during treatment 
weeks 0, 6, 26, 52, and 119. 
The quality of life of participants was evaluated with the Visual Analogue Scale 
(VAS) (Scott & Huskisson, 1976), Koskenvuo Quality of Life Scale (Koskenvuo & 
Kaprio, 1979), and the modified (Muhonen et al., 2008) European Quality of Life (EQ-
5D) instrument (The EuroQol Group, 1990). The modified version includes a dimension 
for sleep and excludes mobility. The sleep dimension was included because sleep is 
often disturbed in cases of alcohol dependence and significantly affects quality of life. 
The EQ-5D test covers patients’ anxiety, sleeping, pain, mood, and self-care issues. 
This test was completed during weeks 0, 12, 52, and 119.  
3.3 Study procedures and treatments 
3.3.1 Study procedure and treatment program in studies I–III 
The treatment procedure in studies I–III followed a standardized procedure and 
comprised the targeted use of naltrexone and eight semi-structured CBT sessions that 
were conducted according to a treatment manual (Sinclair & Jakobson, 1996), for which 
the clinicians had received similar training at the clinic. Four sessions were conducted 
40 
 
with a physician (the first, second, fifth, and eighth) and four with a psychologist (the 
third, fourth, sixth, and seventh). The time spent with the physician and the psychologist 
was standardized and was 50–60 minutes per session. The treatment program included 
homework for recognizing triggers for drinking, for developing coping skills, and for 
assessing motivational factors associated with alcohol use. The outline of the treatment 
program in studies I–III is presented in Table 6. The projected interval between each of 
the first 4 sessions was 1 week and between the last sessions 2–4 weeks. Thus, the 
projected length of treatment was 18–20 weeks. However, for practical reasons, further 
follow-up sessions were possible beyond the eighth session when agreed upon between 
the clinic and the patient. Most patients set a goal of becoming moderate drinkers rather 
than totally abstinent. 
Table 6. Outline of the treatment program in studies I–III 
Treatment session Therapy provider Content of the session 
One 
 
Physician Initial interview and assessment 
Information about the treatment 
Treatment contract 
Introducing the drinking diary 
 
Two 
 
Physician Psychoeducation about naltrexone 
Laboratory tests 
 
Three 
 
Psychologist Discussion about drinking habits and triggers 
Constructing a profile of high-risk and low-risk drinking 
situations 
 
Four 
 
Psychologist Teaching the patient to recognize high-risk situations for 
drinking and avoiding these 
Discussion about coping skills and self-regulation skills 
Discussion about pleasurable activities to replace alcohol use 
 
Five Physician Monitoring the use of naltrexone and discussion about coping 
skills  
 
Six Psychologist Monitoring the use of coping skills 
 
Seven 
 
Psychologist Monitoring the use of coping skills 
Discussion about motivational factors related to drinking and 
setting long-term goals 
(Having a spouse at the therapy session, discussion about social 
support) 
 
Eight 
 
Physician Evaluating the change in alcohol use and health 
Laboratory tests if necessary 
Discussion about the possible need for continued treatment 
 
(Sinclair & Jakobson, 1996) 
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3.3.2 Study procedure and treatment program in study IV 
In study IV, participants were randomized 1:1:1 (81 patients/medical group) to receive 
disulfiram, naltrexone, or acamprosate. Doses were 50 mg of naltrexone once a day, 666 
mg of acamprosate three times a day (1998 mg/day, or if the patient’s weight was <60 
kg, 1333 mg/day), or 100–200 mg of disulfiram once a day, or twice a week. The study 
comprised a 12-week period with continuous medication, followed by targeted 
medication (as needed) for up to 52 weeks, and an additional 67-week follow-up period, 
amounting to 119 weeks (2.5 years). The patients were instructed to use medication 
until week 52, after which it could be either stopped or continued until week 119. 
However, after week 52, the medication was no longer free of charge. The patients 
visited the same physician during weeks 0, 2, 6, 12, 26, and 52. After the end of the 
follow-up period, the participants also had the choice to visit a doctor (week 119). 
At their first visit in study IV, patients received a booklet entitled Winning at Last: 
Defeating the Drinking Problem (Laaksonen et al., 2008b) that they were instructed to 
follow during the study. The booklet was based on the principles of CBT and contained 
motivational components based on self-assessment and goal-setting, as well as relapse 
prevention, life-style change, and problem-solving components. The treatment program 
in study IV is outlined in Table 7. The components and related homework assignments 
were discussed at each of the four initial visits with the doctor (during the first 12 
weeks). 
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Table 7. Outline of the treatment program (sessions 1–4) and follow-up sessions in study IV 
Treatment session Therapy provider Content of the session 
One (week 0) 
 
Physician Initial interview and assessment  
Introduction of the treatment program and the booklet 
Measuring openness to change 
Random assignments to medication groups (by an 
independent person) 
Laboratory tests and other measures 
 
Two (week 2) 
 
Physician Identification of high-risk situations 
Safe situations and previous successes 
Coping with dangerous situations and self-regulation 
To reduce or give up? Long-term goals 
Measures 
 
Three (week 6) 
 
Physician Improving the use of leisure time 
Social support for change 
Problem solving without alcohol 
Laboratory tests and other measures 
 
Four (week 12) 
 
Physician Reviewing the program 
Giving up daily use of medication and continuing with 
targeted medication 
Preventing relapse 
Assessment of the current situation 
Plans for the future 
Measures 
 
Five (week 26) 
 
Physician General discussion on the change 
Six (week 52) Physician 
 
General discussion on the change 
Laboratory tests and other measures 
 
Seven (week 119) Physician 
 
Voluntary follow-up session 
Measures 
 
Source: Laaksonen and co-workers (2008b) 
3.4 Statistical analyses 
3.4.1 Study I 
In study I, a multiple imputation method by chained equations (Rubin, 2004) was used 
to fill in the missing items in all pretreatment variables with missing data in order to 
improve the efficiency of data utilization. Treatment entry factors (the number of DSM 
IV alcohol dependence symptoms, the duration of problematic drinking measured in 
years, the total score of the OCDS, and the OCDS factors) predictive of dropout were 
investigated with analyses of covariance, considering the number of attended treatment 
sessions as the dependent variable in all analyses. First, the predominant effects of all 
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predictors were independently explored in the analyses, and then computed adjusting 
for sociodemographic variables.  
The relationships between dropout and treatment-related factors (change in alcohol 
consumption and symptoms of craving) were then tested with additional analyses 
adjusted for gender and age. In the first phase, the number of attended sessions was 
predicted by whether the patient began the treatment by either abstaining for two weeks 
or continuing to drink, and in the second phase they were predicted by the average 
alcohol consumption measured during the last week of the treatment (week 20) while 
covarying for pre-treatment consumption. The method of last observation carried 
forward was used to replace missing values of dropouts for week 20. In the third phase, 
they were predicted by the VAS score of the last therapy session while covarying for the 
VAS score measured at the beginning of treatment. Finally, in the fourth phase they 
were determined by the adherence to medication use, and in the fifth model, in order to 
control for the effectiveness of naltrexone, by the interaction between alcohol 
consumption in the last week of the treatment program and medication adherence. The 
statistical analyses in study I were performed using IBM SPSS 18.0 for Windows and 
the statistical software R (Version 2.11.1). 
3.4.2 Study II  
In study II, the changes in weekly alcohol consumption and the VAS scores were 
analyzed using group-based developmental trajectory modeling (Jones & Nagin, 2001; 
Jones & Nagin, 2007). One advantage of group-based trajectory modeling is that it is 
not necessary to have complete cases in repeated measurements and that it is possible to 
approximate complex data distributions. The trajectory model for daily alcohol 
consumption reported in the drinking diaries was analyzed using a zero-inflated Poisson 
model, and the trajectory groups for VAS scores were analyzed using the censored 
normal model. All of the trajectories were also constructed using only data with no 
missing values, and it was observed that the trajectories were very similar, even when 
using the incomplete data.  
The relationship between alcohol and craving trajectories was analyzed with a χ2-
test. A medication adherence percentage was calculated based on the number of times 
patients took naltrexone while drinking divided by the number of measured drinking 
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time points in a diary. Patients were categorized into two groups: those who had good 
adherence (≥80%) to naltrexone in drinking situations and those who had poor 
adherence (<80%). The data on baseline factors were examined to detect any systematic 
patterns for missing values and missing cases.  
Predictors of treatment outcomes were investigated with analyses of multinomial 
logistic regression using alcohol consumption and the VAS trajectories as dependent 
variables, while independent variables consisted of gender, age, drinking pattern, 
alcohol consumption risk level, adherence with medication, the total score of the OCDS, 
the number of DSM-IV alcohol dependence symptoms, the total score of the BDI, the 
number of years with problematic drinking, the presence of medical/psychiatric 
comorbidity, the presence of a strong family history of alcoholism, and a history of 
previous treatments. Second, the analyses were performed adjusting all of the models 
for age, gender, medication adherence, and the number of attended CBT sessions. Third, 
in order to examine the potential moderating effect of a family history of alcoholism and 
baseline craving on the association between naltrexone use and the treatment outcome, 
interaction analyses were performed by using interaction terms of these variables and 
medication adherence as independent variables, and the drinking and craving 
trajectories as dependent variables. The statistical analyses in study II were performed 
using IBM SPSS 18.0 for Windows and the PROC TRAJ procedure in SAS 9.2. 
3.4.3 Study III  
In study III, similar to the procedure used in study II, adherence to the use of 
naltrexone before situations of drinking was calculated as a percentage of the number of 
times a patient took naltrexone prior to drinking divided by the number of measured 
drinking time points in the patient diary. Patients were categorized into two groups: 
those who had good adherence (≥80%) to naltrexone in drinking situations and those 
who had poor adherence (<80%). A patient’s compliance with reporting naltrexone use 
in the drinking diary during the treatment was calculated as a percentage of number of 
weeks with complete drinking diary data divided by the number of weeks the patient 
stayed in the treatment during the first 20 weeks of the treatment program, and the data 
were examined to detect any systematic patterns in missing values and missing cases.  
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Logistic regression analyses were used to determine first the unadjusted relationships 
between socio-demographic (age, gender, marital status, employment, and education), 
clinical (primary drinking pattern, pre-treatment alcohol consumption level, and 
comorbid disorders), and alcohol-related or psychiatric variables (DSM IV alcohol 
dependence symptoms, alcohol craving measured by the OCDS and the VAS, and 
depression measured by the BDI) at the treatment entry and medication adherence 
status. The analyses were also performed when adjusting all of the models for socio-
demographic variables. Finally, DSM IV alcohol dependence symptoms, the OCDS, 
and the BDI were examined simultaneously by including them in a multivariate analysis 
adjusted for socio-demographic variables. All of the above analyses were also 
performed with linear regression models using log-transformed continuous medication 
adherence as a dependent variable.  
3.4.4 Study IV  
The average alcohol intake per week, BDI, DEPS, quality of life -tests, and smoking 
habits were analyzed using a per protocol analysis that included all the patients who 
completed the study. The groups’ average weekly alcohol consumption rates were 
analyzed by analysis of variance for repeated measures to examine differences at each 
time point using PROC MIXED in statistical software SAS version 8.2. To control for 
individual differences at baseline, the baseline values of all variables were added to the 
model as covariates. 
All p-values concerning treatment group comparisons were Bonferroni adjusted. 
Descriptive statistics were calculated for all variables. Categorical variables were listed 
in frequency tables by group (PROC FREQ in SAS), and the numerical variables were 
tabulated by group (PROC UNIVARIATE in SAS) (Medicalla). In addition, logistic 
regression models were fitted to the data to explore the effects of different medications 
on quitting smoking during treatment. In the models, smoking was considered as a 
binary (yes/no) response variable, and using medication (yes/no) as a fixed explanatory 
variable. The confounding effect of drinking was investigated by introducing alcohol 
consumption during the last 10 weeks to the models as an explanatory variable.  
To control for selective dropout, patient attrition was analyzed by comparing the 
initial demographic, drinking, BDI, DEPS, and quality of life data of those who had 
46 
 
dropped out of the study with those who could be measured at weeks 12 and 52 using 
the Mann–Whitney U-test. In addition, differences in depression between medical 
groups were examined during weeks 26 and 52 using the Kruskal–Wallis test (PROC 
NPAR1WAY in SAS version 9.2). The missing results from patients who withdrew 
from the study were replaced by their initial BDI values. Finally, Fisher’s test was used 
to analyze differences in keeping a drinking diary between those who dropped out and 
those who completed the study. 
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4 RESULTS 
4.1 Study I: Predictors of dropout in an outpatient treatment for 
problem drinking including CBT and naltrexone 
A total of 196 (53%) of the 372 patients dropped out prior to completion of the basic 
treatment program (8 sessions). Drinking diary data were available for 299 (80%) of the 
patients in the sample of study I. For the 20% of the patients who had no drinking diary 
data, a systematic pattern was observed in relation to the number of treatment sessions 
attended (p < 0.001). Those who did not commit to keeping the drinking diary were 
likely to drop out from the treatment earlier. 
As Table 8 demonstrates, younger patients, those with lower resistance/control 
impairment and obsession over alcohol, and those who had fewer symptoms of alcohol 
dependence dropped out from the treatment program earlier. Those who had a high or 
higher intermediate education were more likely to drop out earlier than those who had 
lower intermediate education. Treatment-related predictors of dropout were starting the 
program by abstaining from alcohol (F(1,283) = 4.26, p < 0.05) and having lower 
adherence to naltrexone (F(1,304) = 53.09, p < 0.001). The number of attended sessions 
was not predicted by alcohol consumption, the patients’ intensity of craving during the 
treatment, or the interaction between alcohol consumption and naltrexone adherence.  
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4.2 Study II: Predictors of outcome in an outpatient treatment 
for problem drinking including CBT and naltrexone 
Using the Schwarz’s information criteria (BIC) and the logarithm of Bayes factor     
(-2log(B10), five growth-curve classes were created for average weekly alcohol 
consumption and craving (Figures 1–2). Inter-correlations between different potential 
predictors of treatment outcomes are presented in Table 9. 
 
 Figure 1. Trajectories of patients’ alcohol consumption during CBT & naltrexone treatment 
 
 
     Figure 2. Trajectories of patients’ cravings for alcohol during CBT & naltrexone treatment 
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A statistically significant, negative linear trend was observed for the alcohol 
consumption trajectories “light start – steady declining” (Beta = -0.0287, p < 0.001) and 
“heavy start – steady declining” (Beta = -0.0177, p < 0.001). A statistically significant 
negative linear trend in cravings for alcohol was observed for all patient groups: “low 
start – steady declining” (Beta = -0.0287, p < 0.001), “moderate start – moderate 
declining” (Beta = -0.471, p < 0.001), “very high start – rapid declining” (Beta = -
0.0452, p < 0.05),  “very high start – steady declining” (Beta = -1.41, p < 0.001), and 
“very high start – moderate declining” (Beta = -0.730, p < 0.001). 
As presented in Table 10, poorer adherence with naltrexone predicted belonging to 
trajectories with higher alcohol consumption compared to “light drinkers”, which was 
used as a reference group in all analyses. The average (mean) medication adherence was 
92% in the trajectory “light drinkers”, 80% in the trajectory “light start – steady 
decline”, 74% in the trajectory “medium heavy start – moderate decline”, 71% in the 
trajectory heavy start – moderate decline” and 76% in the trajectory “heavy start – 
steady decline”. Regular drinking patterns, higher-risk pretreatment alcohol 
consumption and having no history of previous treatments predicted belonging to 
trajectories “heavy start – moderate decline” and “medium heavy start – moderate 
decline”, in which no negative linear trend was observed in alcohol consumption 
compared to the trajectory “light drinkers”. High cravings measured by the OCDS 
predicted belonging to trajectories of “medium heavy” or “heavy start” alcohol use 
compared to “light drinkers”. Lower depression predicted belonging to the trajectory 
“light start – steady decline” compared to the trajectory “light drinkers”. In the fully 
adjusted models, all of the other associations remained significant, except the 
association between higher-risk pretreatment alcohol consumption and belonging to the 
trajectory “medium heavy start – moderate decline”, which was attenuated to non-
significant (p = 0.10), and the association between a higher OCDS score and belonging 
to the trajectory “medium heavy start – moderate decline”, which was also attenuated to 
non-significant (p = 0.08).   
The predictors of belonging to different craving trajectories are presented in Table 
11. Those with lower-risk pretreatment alcohol consumption in comparison to those 
with higher-risk pretreatment alcohol consumption were more likely to belong to the 
VAS trajectory “very high start – rapid declining” compared to the trajectory “low start 
52 
 
– steady declining”, which was used as the reference group in all analyses. None of 
those with lower-risk pretreatment alcohol consumption level belonged to the trajectory 
“very high start – moderate declining”, which presented the highest symptoms of 
cravings. Those who had more severe alcohol dependence were more likely to belong to 
the VAS trajectories “very high start – moderate declining” and “very high start – 
steady declining” compared to the trajectory “low start – steady declining”. In the fully 
adjusted models, all of the other associations remained statistically significant except 
the association between the previous treatment history and belonging to the trajectory 
“moderate start – moderate declining”, which was statistically significant (p = 0.03) 
after the adjustments. Those without a previous treatment history were more likely to 
belong to the trajectory “moderate start – moderate declining” compared to the 
trajectory “low start – steady declining”. In the final models testing the potential 
moderating effect of a family history of alcoholism and baseline craving on the 
association between naltrexone use and the treatment outcome, no statistically 
significant associations were found between the study variables. 
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4.3 Study III: Predictors of medication adherence in an outpatient 
treatment for problem drinking including CBT and naltrexone 
The average medication adherence in situations of alcohol use during the first four months of the 
treatment was 78% (SD = 21). Figure 3 illustrates the distribution of medication adherence among 
patients: 178 patients (59.5%) used naltrexone in 80% or more of the drinking situations and were 
categorized as having good adherence; 121 patients (40.5%) used naltrexone in less than 80% of the 
drinking situations and were categorized as having poor adherence. As expected, those patients who 
were less committed to keeping a drinking diary were more likely to belong to the group of lower 
medication adherence (χ2(1) = 31.87, p < 0.001).  
Poor naltrexone adherence was associated with being unemployed (adjusted OR 0.43, 95% CI: 
0.22–0.86, p = 0.02), having higher symptoms of alcohol craving measured by the total score of the 
OCDS (adjusted OR 0.94, 95% CI: 0.90–0.98, p < 0.01) and VAS (adjusted OR 0.86, 95% CI: 
0.92–1.01 p < 0.001), the OCDS factor “resistance/control impairment”, and with a higher number 
of alcohol dependence symptoms (adjusted OR 0.87, 95% CI: 0.73–1.02, p = 0.04). Adjusting the 
models for sociodemographic variables did not change the associations between these variables. In 
the linear regression models, all of the above results remained the same, except for the association 
between the DSM IV alcohol dependence symptoms (b = 0.01, t(242) = 1.25 , p = 0.21).  In the 
multivariate model assessing the relative contribution of the DSM IV alcohol dependence 
symptoms, the total score of the OCDS and the BDI on medication adherence, the total score of the 
OCDS remained statistically significant (p < 0.05) in the unadjusted model as well as in the model 
adjusted for socio-demographic variables, whereas the DSM IV alcohol dependence symptoms did 
not.  
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Figure 3. Adherence of patients to targeted (used as needed, i.e. only in drinking occurrences) medication use 
in a CBT and targeted naltrexone treatment 
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4.4 Study IV: Combining medical treatment and CBT in treating alcohol 
dependent patients: effects of treatment on quality of life and general 
well-being 
By the end of the first 12-week study period, 25.1% of the patients in study IV had dropped out, and 
by the end of the study (52 weeks), the dropout rate was 51.8%. There were no significant 
differences in the completion of the study between the different medication groups. The socio-
demographic background of participants was similar in all medication groups. Detailed information 
has been published previously by Laaksonen and co-workers (2008a). Dropping out from the 
treatment was associated with a younger age and lower persistence in keeping a drinking diary. 
All three study groups showed a significant reduction in drinking from baseline to the end of the 
study. As was demonstrated in the earlier trial by Laaksonen and co-workers (2008a), treatment 
with disulfiram was more effective than acamprosate or naltrexone in reducing heavy drinking and 
average weekly alcohol consumption, and in increasing the time to the first drink, as well as the 
number of abstinent days (Figure 4). AUDIT and SADD scores indicated significant reductions 
during the study (p < 0.0001) in the severity of the alcohol problem and in alcohol dependence.  
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Figure 4. Number of drinks per week at baseline and on follow-up, 0–119 weeks. (Disulfiram, DIS; naltrexone, 
NAL; acamprosate, ACA). 
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The improvement in the QL scores was statistically significant for VAS (F(3,215) = 20.14, p < 
0.001), KQL (F(3,220) = 21.76, p < 0.001) and EQ-5D dimensions of sleep (Wald χ2 = 19.69, df = 
3, p < 0.001), the ability to act (Wald χ2 = 25.38, df = 3, p < 0.001, pain (Wald χ2 = 8.64, df = 3, p < 
0.05), and mood (Wald χ2 = 31.40, df = 3, p < 0.001) over the whole study period (52 weeks and 
follow-up), with no differences between the groups. However, in subscales of self-care, there were 
no significant differences between medical groups or with time (Wald χ2 = 2.98, df = 3, p = 0.39). 
Both of the depression scales, BDI (F(4,222) = 44.18, p < 0.001) and DEPS (F(4,222) = 38.92, p < 
0.001), also showed that depression scores decreased significantly during the whole study period 
when compared to the first visit. However, no significant differences were found between medical 
groups.  
As is shown in Table 12, a significant reduction in the proportion of patients who reported 
smoking was seen in the disulfiram group during the first 26 weeks (from 55.7 to 35.1%), and again 
at 52 weeks (from 55.7 to 34.3%), compared with the naltrexone group (p < 0.001) and acamprosate 
group (p < 0.02). No such drop was seen in the naltrexone or acamprosate groups. The logistic 
regression model revealed that using disulfiram had a statistically significant effect on smoking at 
treatment week 52 (p = 0.008). At treatment week 52, naltrexone and acamprosate users were three 
times more likely to smoke compared with the disulfiram users (OR = 3.06). Including patients’ 
alcohol consumption during the previous 10 weeks in the model did not have a confounding effect 
on the results. 
 
Table 12. Percentage of smokers during treatment weeks 0–52.  
Medication 
group 
Smoking 
Yes/No 
0 weeks         12 weeks      26 weeks        52 weeks 
N % N %  N % N % 
Acamprosate Yes 42    51.9      30    53.6      21    50.0      22    53.7 
No 39    48.1      26    46.4      21    50.0      19    46.3 
Disulfiram Yes 44   55.7      25    47.2      13    35.1a      12    34.3a 
No 35    44.3      28    52.8      24    64.9      23    65.7 
Naltrexone        Yes 58    72.5      40    69.0      25    59.5      29    69.0 
No 22    27.5      18    31.0      17    40.5      13    31.0 
Total Yes 144    60.0      95    56.9      59    48.8b     63   53.4b 
No 96    40.0      72    43.1      62    51.2      55    46.6 
a Significantly more patients using disulfiram stopped smoking than patients using naltrexone (compared to disulfiram, 
p < 0.001) and acamprosate (p = 0.015).  
bThe reduction in smoking habits (total) was most prominent during weeks 26 and 52.  
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5 DISCUSSION 
Randomized controlled trials form the basis for planning evidence-based treatment guidelines in 
alcohol treatment. Studies based on routinely collected data and non-randomized study samples 
have been suggested as an important adjunct to randomized controlled trials (Moyer & Finney, 
2002; Rothwell, 2005), but such studies are scarce.  
This study investigated how one evidence-based treatment for problem drinking, a combination 
of cognitive behavioral therapy and targeted naltrexone (Hernandez?Avila et al., 2006; Kranzler et 
al., 2009), works in a community outpatient treatment setting. Specifically, the purpose of the study 
was to identify predictors of treatment outcomes. The study aimed to contribute to what Rothwell 
(2005) argued was needed in the field of treatment intervention research: studies reporting 
determinants related to external validity, i.e. reporting to whom the results of evidence-based 
treatments apply. Another purpose of this study was to investigate how the combination of 
pharmacotherapy (naltrexone/acamprosate/disulfiram) and CBT can improve the well-being and 
quality of life of patients, in addition to reducing alcohol use. 
This study demonstrated that although many randomized controlled trials (e.g. Anton et al., 
2005; Heinälä et al., 2001; Hernandez-Avila et al., 2006; Kranzler et al., 2009; O'Malley et al., 
1992; Oslin et al., 2008) have proven CBT and naltrexone to be an efficacious treatment for 
problem drinking, there may be variability in the effectiveness of this treatment in real-life 
treatment settings including heterogeneous patient samples. The study also identified several 
predictors of treatment dropout, treatment outcomes, and patient adherence to medication. 
Furthermore, this study revealed that in addition to a reduction in drinking, the combination of 
medication and CBT can improve general well-being and quality of life for those patients who 
commit to treatment. The treatment may also help patients to quit smoking, especially those who 
use disulfiram during treatment. 
5.1 Predictors of treatment dropout 
The study demonstrated that those with a less severe alcohol dependence, lower obsession with 
alcohol, and a better ability to resist and control their drinking were likely to drop out from the 
treatment. Those who started the treatment with abstinence instead of continuing to drink were also 
at a higher risk of dropout. The dropouts had lower adherence with naltrexone and reporting their 
alcohol use in drinking diaries. 
The fact that patients with less severe alcohol dependence and a lower craving for alcohol had a 
higher risk of dropping out from the treatment is noteworthy, because dropping out is typically 
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perceived as a sign of noncompliance, resistance, or a failure of treatment (Pulford et al., 2006). 
However, as Pulford and co-workers (2006) pointed out, dropout can also be understood as a failure 
of treatment fit, meaning that the patient may leave because the treatment is not optimal to his or 
her presenting problem. Patients with better control over their drinking behavior may be more 
motivated and have better retention in brief interventions, which have proven effective for those 
with less severe problems (Moyer et al., 2002). One alternative explanation for higher risk of 
dropout of those with less severe alcohol problems may be that these patients are not yet concerned 
about their drinking behavior. Namely, the severity of the alcohol problem appears to increase 
feelings of distress about the problem and thereby influence decision making about treatment (Ryan 
et al., 1995). It should be noted that perceived control over alcohol use may also be a sign of over-
confidence. Namely, the work of Burling and co-workers (1989) indicated that those with high 
alcohol-related self-efficacy were likely to drop out from treatment, despite not having successful 
outcomes on alcohol-related measures.  
The study also observed that dropping out from the treatment was related to a younger age. The 
same finding has been reported in several previous studies (Brorson et al., 2013; Elbreder et al., 
2011; Mammo & Weinbaum, 1993; McKellar et al., 2006; Wickizer et al., 1994). One explanation 
for possibly lower motivation for treatment among younger patients may be that they have 
experienced fewer adverse consequences related to alcohol use (McKellar et al., 2006). They may 
still be in a contemplation stage of change (see Norcross et al., 2011), balancing between the pros 
and cons of their drinking behavior. 
The patients who chose abstinence at treatment entry were more likely to drop out from the 
treatment than those who continued to drink. Using naltrexone during abstinence has not been 
proposed to be useful (Sinclair, 2001). Therefore, a manualized treatment program based on 
targeted medication and a progressive reduction in drinking rather than abstinence may not be 
beneficial for patients who choose not to drink upon entry to treatment. Although it should be noted 
that most of the therapists would try to adjust the treatment program to the patients’ situation, the 
changed structure of the program may lead to some degree of confusion in therapy, and thereby to 
less commitment to treatment on the patients’ part.  
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5.2 Effectiveness of treatment and predictors of alcohol-related 
outcomes 
Similarly to the systematic reviews by Adamson and co-workers (2009) and McKay and Weiss 
(2001), the pretreatment alcohol consumption level was a significant predictor of treatment 
outcomes in study II. A higher level of pretreatment drinking was associated with poorer drinking 
outcomes during the treatment, and a lower level of pretreatment drinking was associated with the 
most rapid reduction in craving for alcohol. Patients who drank more alcohol before and during the 
treatment had lower adherence to naltrexone. A lower reduction in alcohol consumption was also 
observed for those with no history of previous treatments.  
The patients in the treatment program of studies I–III were generally encouraged to continue 
drinking progressively down to lower levels or to abstinence during the treatment, as suggested by 
Sinclair (2001). However, 23% of the patients started and continued the treatment with minimal 
alcohol consumption. A marked reduction in alcohol consumption was observed for a further 32% 
of the patients. For the remaining 45% of the patients, the effect of the treatment appears to have 
been modest compared to the results demonstrated in randomized controlled trials of targeted 
naltrexone and CBT (Kranzler et al., 2003; Kranzler et al., 2009). However, it should be noted that 
patients were encouraged to set their own treatment goals and many chose to reduce their drinking 
below the hazardous drinking levels suggested in the Finnish guidelines for problem drinking (Alho 
et al., 2011).  
It is also noteworthy that the patients who started with most excessive drinking belonged to the 
group that had better outcomes. These may have represented a subgroup of patients who derived 
most benefit from naltrexone. Namely, naltrexone has been found to be especially beneficial for 
heavy or excessive drinking (Pettinati et al., 2006b). In accordance with the treatment goals of 
naltrexone (Rösner et al., 2010) and CBT (Marlatt & Gordon, 1985), a significant reduction in 
craving for alcohol was observed for all patients in study II. These results confirm the proposal by 
Tiffany and Conklin (2000) that patterns of alcohol use can operate independently of craving. 
Study IV revealed a significant reduction in drinking in all three medication groups during the 
first 12 weeks of the treatment, and the results remained the same until the end of the treatment, at 
119 weeks. One reason for the seemingly poorer treatment outcomes in study II compared to study 
IV is likely to be related to methodological differences. In study IV, only patients who completed 
the treatment were included in the analyses, whereas in study II those who dropped out were also 
included in the alcohol consumption trajectories. In study IV, those who continued with the 
treatment for as long as 52–119 weeks were likely to be the ones who most benefited from the 
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treatment. Namely, those receiving a rapid initial response and individual care are likely to remain 
in treatment (Stark, 1992), and there is evidence that the time spent in treatment correlates with a 
positive post-treatment outcome (Gottheil et al., 1992; Moos & Moos, 2003; Welte et al., 1981). 
Another reason for the differences in the outcomes of studies II and IV is likely to be associated 
with the different mediation adherence rates. Because study IV was a clinical randomized trial, 
patients received their study medication at no cost and their medication compliance was assessed 
with pill counts. The average naltrexone adherence rate was 82.5% (Laaksonen et al., 2008a) 
compared to the adherence rates of 71–74% that were observed in trajectories with the most modest 
alcohol consumption reduction in study II. Finally, in study IV, only those with a history of heavy 
drinking were invited for the trial, whereas in study II, those with lower pretreatment alcohol 
consumption levels were also included. Therefore, there was high variability in the baseline alcohol 
consumption levels in study II compared to study IV.  
The reason why those without any history of previous treatment were most likely to have a 
modest reduction in alcohol consumption remains unclear. One possible reason for this finding may 
be that these patients may have experienced fewer adverse consequences related to their drinking 
behavior and consequently have a lower motivation to reduce their alcohol use. In a systematic 
review by Adamson and co-workers (2009), treatment history showed significant variability in the 
direction of association relative to treatment outcomes. In three of the reviewed studies, more 
treatment was related to better outcomes, whereas in five studies, better outcomes were associated 
with less treatment.  
5.3 Adherence to naltrexone use  
Study II revealed that the alcohol consumption level among patients during the treatment was 
inversely associated with adherence to targeted naltrexone. Baseline predictors of poor adherence 
with naltrexone included unemployment and a high craving for alcohol at treatment entry, 
particularly difficulty in resisting alcohol-related impulses and controlling drinking behavior. 
As suggested above, one probable reason for the considerable variability in alcohol-related 
outcomes was likely to be the differences between patients in their adherence to naltrexone use. 
Although the overall adherence rate was 78%, adherence was much lower, 71–74%, in trajectories 
with the most modest reduction in alcohol consumption. This is in line with results reported by 
Gueorguieva and co-workers (2013), who observed that lower adherence was related to greater 
drinking severity during treatment. In contrast, those who continued to drink only moderately 
during treatment were most compliant in using the medication. Considering that the effect of 
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naltrexone is associated with medication adherence (Baros et al., 2007; Chick et al., 2000; 
Volpicelli et al., 1997), poor adherence with naltrexone is a notable obstacle to the effective 
pharmacological treatment of problem drinking in real-life treatment settings. Poor medication 
adherence among hazardous drinkers has been demonstrated previously (Cook et al., 2001).  
Very little data are available to indicate the extent to which patients in real-life clinical practices 
adhere to using medications for alcohol dependence. In natural treatment settings, medication 
adherence is likely to be much lower than in clinical trials, in which medication use is usually 
intensively monitored and the participants receive their study medication at no cost. Therefore, the 
average naltrexone adherence rate of 78% during the 4 months of the treatment can be considered 
relatively high in the light of the results of Kranzler and co-workers (2008) and Hermos and co-
workers (2004), who reported that only 14–22% of the patients who filled an initial prescription for 
naltrexone persisted in obtaining the medication after 6 months. 
Possible reasons for the comparatively high overall medication adherence may be that the 
treatment program included psycho-education on the neurobiological effects of naltrexone, and the 
clinic and its staff were all specialized in this treatment model. Educational approaches have been 
found to be most effective when used in combination with behavioral and supportive services 
(Zygmunt et al., 2002). Also, as Pettinati (2006a) pointed out, a clinician’s attitude concerning the 
effectiveness of a medication is critical, because it may be transferred to the patient. Another reason 
for the good overall medication adherence may be related to using naltrexone in a targeted manner 
instead of as a daily dose, since the prescribed dosage has proven to be inversely related to 
compliance (Claxton et al., 2001). In particular, patients who are not drinking on a daily basis may 
find it difficult to motivate themselves to use daily medication.  
Reasons for the poor naltrexone adherence of those who were unemployed may include the cost 
of the medication and lower social support, which have both been shown to be associated with 
lower adherence to medication (Balkrishnan, 1998; DiMatteo, 2004). The association between high 
craving for alcohol at treatment entry and poorer naltrexone adherence may be somewhat less 
straightforward. The use of naltrexone is associated with decreased pleasurable effects of alcohol 
(Rösner et al., 2010), and some patients might have competing and contrary motivations in giving 
up these effects. However, different subtypes of patients may have different neurobiochemical 
mechanisms underlying their symptoms of craving (Addolorato et al., 2005), and reasons for not 
taking the tablet may vary accordingly. There is also evidence that patients with substance 
dependence have problems in the executive processes of working memory (Bechara & Martin, 
2004), which may have caused patients struggling with high alcohol craving, in particular, to simply 
forget to take the pill. One reason for not taking the medication may be associated with alcohol-
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related outcome expectancies. These include positive ones, such as social interaction, fun, and 
tension reduction (Monk & Heim, 2013), which a person may perceive as diminished when taking 
the medication. 
 
5.4 Effects of alcohol treatments on quality of life, smoking habits, and 
depression  
The results of study IV demonstrated that, in addition to a significant reduction in drinking, the 
combination of medication (naltrexone, acamprosate, or disulfiram) and CBT can improve sleeping, 
quality of life, and depression for those patients who commit to treatment. The dimensions of the 
quality of life that were improved during the treatment included mood, sleeping, the ability to act, 
and pain. The improvement was similar across medication groups. Moreover, although a reduction 
in smoking rates was observed in all medication groups by treatment weeks 26 and 52, those who 
used disulfiram were more successful in quitting smoking than those who used naltrexone or 
acamprosate. 
These findings are important considering that the comorbidity of depressive symptoms in 
association with problematic alcohol use is associated with an increased risk of relapse after 
treatment (Curran et al., 2000; Driessen et al., 2001), and the presence of either alcohol use disorder 
or major depression doubles the risk of a second disorder (Boden & Fergusson, 2011). Although 
this study did not control for patients’ antidepressant medication use, it is plausible that some of the 
patients received antidepressant medication while in treatment. Previous research has demonstrated 
that combined pharmacotherapies for alcohol dependence and depression can reduce the symptoms 
of both disorders (Pettinati et al., 2010). It has also been demonstrated that the treatment of alcohol 
use disorder results in a reduction in depressive symptoms (Brown & Schuckit, 1988), which may 
be one reason for the positive outcomes in depression observed in this study.  
Improvement in patients’ sleeping is also important, because it has been shown that sleep 
disturbances increase the risk of relapse (Roehrs & Roth, 2001). The observed improvement in 
other measures of QL, the ability to act and experience of pain, are also noteworthy, because QL 
among alcohol-dependent patients is known to be poor compared to general population norms 
(Foster et al., 1999). 
This is to the best of our knowledge the first study to report an association between successful 
quitting of smoking and the use of disulfiram, in particular, during treatment. The finding was not 
only explained by the change in alcohol consumption, which was most reduced in the disulfiram 
group in an earlier study by Laaksonen and co-workers (2008a). One of the possible explanations 
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for the effect of disulfiram on reduced smoking may be related to the inhibition of dopamine beta-
hydroxylase, which is associated with the use of disulfiram (Lippmann & Lloyd, 1969), and which 
may lead to reduced pleasure associated with smoking. Another explanation may be associated with 
the combined effect of disulfiram and tobacco smoke. The use of disulfiram and exposure to 
tobacco smoke are both associated with the accumulation of acetaldehyde in the body (Heilig & 
Egli, 2006; Salaspuro & Salaspuro, 2004), which may lead to more side effects in alcohol-
dependent smokers using disulfiram than in those using naltrexone or acamprosate. The observed 
effects of the treatment on quitting smoking were observed during treatment weeks 26 and 52, 
suggesting that longer treatment may be needed to achieve these results. There is high comorbidity 
in nicotine and alcohol dependencies (Grant et al., 2004), and the smoking status among alcoholics 
appears to increase the odds of relapse (Baltieri, et al., 2009). Therefore, this result may have some 
important clinical implications.  
5.5 Methodological considerations 
5.5.1 Strengths of the study 
The foremost strength of studies I–III was their high external validity and good generalizability of 
the findings to real-life treatment practice. Due to the minimal exclusion and inclusion criteria, the 
patient sample included those with psychiatric and medical disorders, which are typical in problem 
drinkers. The lack of a randomization procedure was likely to have improved the external validity 
of the results. Namely, it has been indicated that participants in randomized versus self-selected 
samples often differ at baseline (Moyer & Finney, 2002) and e.g. low-income individuals, and 
individuals who have more severe substance abuse or psychiatric problems are disproportionately 
excluded from alcohol treatment trials in comparison to real-world samples seen in clinical practice 
(Humphreys & Weisner, 2000). A methodological strength in study II included the use of trajectory 
analyses to describe the changes in alcohol consumption and craving, which has been proposed as a 
valid exploratory method for evaluating the efficacy of pharmacotherapy in alcohol trials (Chen et 
al., 2012). Finally, considering that dropout can impair the internal validity of any trial 
(Leichsenring, 2004), the thorough analysis of the dropouts in study I improved the internal validity 
in these studies.  
Study IV also possessed good external validity compared to typical pharmacological randomized 
controlled trials, because the patients were voluntary treatment-seeking individuals who contacted 
outpatient addiction treatment centers and occupational health-care units, which are typical places 
to take in patients with alcohol problems. Patients who had a history of heavy drinking and accepted 
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the study protocol were recommended for screening, and despite using some exclusion and 
inclusion criteria (see Laaksonen et al. 2008a for further details), only 20 patients out of 277 
screened patients did not meet these criteria and were excluded from the study. The methodological 
strengths of study IV included the fairly large sample size and the long study duration and follow-
up period for those who completed the treatment, lasting 2.5 years in total.  
5.5.2 Limitations of the study 
A major limitation in studies I–III was the large amount of missing data resulting from the data 
having been gathered in a community setting. However, in study I we used the procedure of 
multiple imputations by chained equations (Rubin, 2004), which has been shown to perform 
favorably in situations of missing data (Bryant et al., 1997). When analyzing the drinking diaries in 
study II, we used group-based trajectory modeling, where it is not necessary to have complete cases 
in repeated measurements, and it is possible to approximate complex data distributions. The use of 
trajectory analysis has been found to yield consistent results in the event of data missing at random 
(Chen et al., 2012). In studies II–III, the baseline data were examined to detect any systematic 
patterns for missing values. Another limitation in studies I–II was that patients’ alcohol 
consumption was only estimated for one month preceding entrance to the treatment program, which 
may not accurately reflect typical alcohol use during a longer interval.  
Further limitations in studies I–II include the lack of more objective measures, such as liver 
enzyme values, to evaluate the treatment outcome, the lack of follow-up data on patients’ alcohol 
use or symptoms of craving in the post-treatment period, and the lack of biochemical measures at 
different points of the treatment. In study III, the lack of more sophisticated measures for 
monitoring patients’ medication adherence can be considered a limitation. However, it should be 
noted that the assessment methods in studies I–III, such as the use of drinking diaries, were typical 
of those used in real-life alcohol treatment settings, and despite their methodological shortcomings, 
they possess good external validity. Compliance measurements based on daily diaries have also 
been reported to provide information similar to that obtained using electronic medication-use 
monitoring (Feinn et al., 2003). One limitation in studies I–III was that although it was plausible 
that some of the patients in the studies were likely to continue their attendance at the clinic after the 
20th week of treatment, no data were available for their treatment outcomes after week 20.  
In study IV, limitations included not assessing the patients’ possible antidepressant medication 
use during the treatment and not diagnosing patients using psychiatric criteria. It also remains 
unclear whether the improved QL and depression were associated with patients’ reduction in 
alcohol use and craving. Limitations also included only assessing the patients’ smoking behavior 
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with a simple yes/no question and not by using a validated instrument. A further limitation of study 
IV was the use of per protocol analyses, which only included patients who completed the treatment 
in the analyses. The problem with a per protocol analysis is that it only includes ‘ideal patients’ in 
the analyses, which may lead to bias (Boutis & Willan, 2011). 
One limitation in all four studies was the lack of assessment of potential mediators of the 
treatments. In studies I–II, due to the lack of comparison group(s) and because the role of specific 
active elements of CBT was not examined, the identified predictors of treatment outcomes cannot 
be ascertained to be specific to CBT and naltrexone alone. In all four studies, the role of mediators 
remained unclear. In addition to the active ingredients of the treatment, these include the data 
source, behavior of the therapist, therapist–patient or doctor–patient interactions and relationships, 
and the behavior of the patient (Longabaugh, 2007). Patients’ motivation for treatment and 
motivation for change are likely to have influenced the outcomes in all studies. It has not been 
typical to examine these factors in randomized controlled trials or effectiveness studies, although, as 
suggested by Magill and Longabaugh (2013), clinical research should move towards understanding 
these proven active treatment ingredients and the mechanisms by which a patient changes.  
5.6 Clinical implications of the findings 
An important finding of this study in respect to routine treatment settings was the variability in how 
problem drinkers benefited from CBT and naltrexone. The findings suggest that the patients’ age, 
ability to control alcohol use, pretreatment alcohol consumption level, and treatment goals should 
be used as a basis for planning more effective alcohol treatments. The findings also suggest that 
targeted naltrexone may not be the best choice of medication for everyone. Instead, patients who 
drink heavily in the pretreatment period may benefit more from supervised disulfiram, or starting 
the treatment with daily naltrexone as used in study IV and, for instance, in a study by Heinälä and 
co-workers (2001). Nalmefene, a newer opioid antagonist that has a considerably longer half-life 
than naltrexone (Bart et al., 2005), may show more promising results even for heavy drinkers when 
used in an as-needed manner (Gual et al., 2013; Niciu & Arias, 2013).  
The observed inverse relationship between patients’ medication adherence and the level of 
alcohol consumption in study II confirms the concern raised by Pettinati (2006a), among others, 
related to poor medication adherence among the alcohol-dependent population. Pettinati (2006a) 
suggests that if non-adherence is identified as a problem in treatment, “the clinician should address 
the issue with the patient in order to uncover the rationale behind it in an empathetical and non-
judgmental way.” Accordingly, patients with non-adherence should be offered additional support 
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for enhancing their adherence to medication use, or be provided with alternative medications. As 
was found in a study by Gueorguieva and co-workers (2013), those who exhibited early problems 
with adherence to one treatment modality received better outcomes when offered an alternative 
behavioral or pharmacological treatment. 
It may be important that clinicians acknowledge patients’ high craving for alcohol as one 
potential reason for not taking the medication. In addition, the cost of medication may be an 
important obstacle for medication adherence and should be discussed with the patient. The findings 
also support the use of the pretreatment alcohol consumption level as an important determinant 
when planning treatments for problem drinking. As Rychtarik and co-workers (2000) and Klein and 
co-workers (2002) suggest, improved outcomes may be achieved by matching the degree of alcohol 
involvement or problem severity to the level of care. Observing patients’ alcohol consumption 
during treatment is important. Namely, drinking higher amounts while receiving treatment seems to 
be related to higher drinking in the post-treatment period (Breslin et al., 1997). If the goal of 
treatment is to reduce drinking to progressively lower levels, the length of treatment should be 
adjusted according to the level of progress. Alternatively, although the support for the use of 
inpatient care over outpatient care is inconsistent (Mattick & Jarvis, 1994), patients with the most 
severe alcohol problems may benefit more from inpatient treatment, as suggested by Rychtarik and 
co-workers. (2000), or longer treatment, which has been found to improve the outcomes of those 
with more severe alcohol problems (Gottheil et al., 1992; Moos & Moos, 2003). 
A behavioral intervention, BRENDA (Starosta et al., 2006), has been developed for alcohol-
dependent patients to improve adherence to alcoholism medication. It has 6 components, consisting 
of a biopsychosocial evaluation of the patient’s situation, a report of the findings from the patient 
evaluation, the use of empathy, addressing the patient’s needs, providing direct advice and assessing 
the patient’s reaction to the given advice, and adjusting the treatment plan accordingly (Starosta et 
al., 2006). Contingency management has also been shown to improve adherence to naltrexone 
(Preston et al., 1999). Osterberg and Baschke (2005) noted the possibilities that come with new 
technology, such as cell phones, personal digital assistants and pillboxes with paging systems in 
helping patients to meet the goals of medication adherence.  
It has been suggested that it is important to discuss patients’ drinking goals when they enter 
treatment and use this information as a basis for negotiation (Adamson et al., 2010). Clinicians 
should be also prepared “to identify and support goal change as an unexceptional part of the 
treatment process that need not jeopardize good outcome” (Adamson et al., 2010). Medications 
should then be targeted on the basis of the goal of the treatment (Alho & Aalto, 2013).  
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Klein and co-workers (2002) emphasized the importance of taking into account patients’ 
demographic factors when planning treatment. The findings of this study suggest that younger 
patients may need special attention in order to enhance their retention in treatment. Although 
motivation for changing a problematic behavior is not necessarily synonymous with motivation for 
participating in treatment (DiClemente et al., 1999), with younger patients it may be particularly 
important to discuss motivational factors related to their drinking behavior. 
One factor in improved treatment planning is to take account of the stage of change in the patient 
at treatment entry. A meta-analysis of 39 studies by Norcross and co-workers (2011), including 
several alcohol trials, reported clinically significant effect sizes for the association between the 
patients’ stage of change and psychotherapy outcomes. It was also suggested that clinicians should 
treat all patients as though they are in action, and when planning the treatment always take account 
of the patients’ current stage of change. 
Our findings demonstrated that those who chose abstinence were more likely to drop out of 
treatment than those who continued to drink. One of the reasons for this may have been the use of a 
manualized study protocol. Patients who have good control over their drinking behavior at an early 
phase of treatment may already have effective coping skills for controlling their alcohol use, and 
may find irrelevant or unnecessary tasks in therapy frustrating. Although treatment manuals are 
important in randomized controlled trials, in real-life treatment settings they may be less appropriate 
(Addis et al., 2006). At least a rigid use of a therapy manual may miss the amount of variance 
attributed to patient variables and nonspecific factors of therapy (Addis et al., 2006), which have 
been proven to account for a considerable amount of the treatment outcome (Connors et al., 1997; 
Schneider et al., 2004; Wampold, 2001). However, it should also be noted that a clear structure and 
well-defined interventions appear to have favorable effects on the treatment of alcohol dependence 
(Berglund et al., 2003). Therefore, therapy manuals may be best used in a flexible way, taking into 
account the patients’ individual situation. 
The positive effects of a combination of medical treatment and CBT for general well-being and 
smoking habits may have important clinical implications. They indicate that the alcohol-dependent 
patients who smoke may benefit from the use of disulfiram in helping them to quit smoking, in 
addition to reduced alcohol use. Another important implication of these findings may be related to 
the length of the alcohol use treatments. Considering that the positive result for smoking was 
observed in the 26th week of the treatment, a longer treatment period may be needed to achieve this 
result. However, longer treatment does not mean that the treatment should be intensive. As Moos 
and Moos (2003) reported, the continuity and duration of treatment may be more important for 
achieving good outcomes than its intensity. 
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5.7 Conclusions and suggestions for future research 
In conclusion, the results demonstrate that there is relatively large variability in how problem 
drinkers benefit from CBT and naltrexone in real-life treatment settings. The results of randomized 
controlled alcohol trials may not be directly generalized to routine clinical practice, and more 
research is needed on testing the evidence-based alcohol treatments using data of heterogeneous 
patient samples with typical comorbidities.  
According to the results, younger patients and those with lower alcohol dependence may lack 
motivation or not need long CBT and targeted naltrexone treatment, and they may be at a higher 
risk of prematurely dropping out from the treatment. Having good control over alcohol use and 
being able to abstain from drinking in the early phase of the treatment may also indicate a higher 
risk of dropout. Patients with less severe alcohol dependence and better control over drinking may 
benefit from less intensive or shorter treatments or need motivational interventions (e.g. Roche et 
al., 1995) in order to enhance their treatment retention.  
In contrast, this study showed that patients who have no previous treatment history and those 
with a high pretreatment consumption level and higher level of drinking during the treatment may 
be at risk of having poorer outcomes. These patients may need longer or more intensive care in 
order to reduce their drinking, or alternative medications to the targeted use of naltrexone. The 
results also demonstrate that poor medication adherence is a considerable obstacle to the effective 
treatment of alcohol problems in a real-life treatment setting. Excessive drinking during the 
treatment may be associated with poor adherence to naltrexone, and heavy drinkers may therefore 
need specific interventions to enhance medication adherence. 
One finding of this study was that unemployed patients with a possible lack of financial 
resources and low social support may have difficulty in adhering to medication. A high craving for 
alcohol may also lead to poor medication adherence. It may be important to pay attention to these 
factors when evaluating the patient’s willingness to use medication. 
Finally, the study indicated that for those who commit to treatment, the combination of 
medication and CBT can improve smoking habits, sleeping, quality of life, and depression, 
alongside a reduction in drinking. Specifically, the use of disulfiram during treatment may help 
patients to quit smoking, in addition to reducing their alcohol use.  
The results of this study confirm earlier proposals (Breslin et al., 1997; Sobell & Sobell, 2000) 
that treatments should be better adjusted to the patients’ individual needs, both at treatment entry 
and during the course of the treatment, using the best possible clinical judgment and the present 
knowledge base. Randomized controlled trials indicate that the treatment of alcohol use disorders is 
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cost-effective (UKATT, 2005b; Zarkin et al., 2008). However, as O’Brien and McLellan (1996) 
pointed out, the expectation of a cure after treatment is unrealistic, and the treatment of addictions 
should be compared to that of other chronic disorders.  
It is clear that the current system of care for alcohol problems often does not respond to the 
diversity of patients, such as the nature and severity of the problem, the resources of the patient, 
treatment preferences, goals, motivations, behavior change pathways, and patient–treatment 
interactions. Future research should include naturalistic studies on these factors. Moreover, although 
a more individualized approach in the pharmacological treatment of the alcohol-dependent 
population is well on its way (Mann & Hermann, 2010b), more research is needed not only on who 
benefits from which medication, but also on the factors related to medication adherence in alcohol-
dependent patients. As Longabaugh (2007) noted, behavior change is a complex process, and 
research needs to reflect this complexity.  
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